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SUMMARY
The present work has investigated the diverse interactions 
of selected methylenedioxyphenyl compounds with hepatic components, both 
in vivo and in vitro.
Many methylenedioxyphenyl compounds were found to be 
activated via the hepatic monooxygenase system, resulting in the formation 
of "active metabolites" capable of binding in a 1:1 ratio with the haem of 
cytochrome P-450. These methylenedioxyphenyl metabolite-cytochrome P-450 
complexes were found to be very stable and could be formed both in vivo 
and in vitro. However, safrole or isosafrole metabolite-cytochrome P-450 
complexes, generated in vivo, were found to be dissociated with relative 
ease in the presence of certain alternative Type I substrates of the mixed 
function oxygenase system. This time-dependent dissociation of the 
complexes was observed after their formation in vivo, but not in vitro.
Safrole and isosafrole appeared to induce the formation of 
a novel haemoprotein of the cytochrome P-448 type. The spectral properties 
of the safrole- or isosafrole-induced haemoproteins were found to be 
similar to but not identical with those of cytochrome P-448.
Isosafrole-related material was found to becon^e bound to
v
other hepatic cellular components in an apparently irreversible manner. 
Results obtained using a novel approach, utilizing isolated hepatocytes, 
were compared with those found in vivo and in vitro using microsomes. The 
data obtained indicated that the use of the isolated hepatocyte system is 
more reliable than the usual in vitro microsomal screen for covalent binding, 
which has many inherent pitfalls.
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You must not say that this cannot be, or that that is 
contrary to Nature.
You do not know what Nature is, or what she can do; 
and nobody knows, not even Sir Roderick Murchison, or Professor 
Owen, or Professor Sedgwick, or Professor Huxley, or Mr. Darwin, 
or Professor Faraday, or Mr. Grove ........... They are very wise
men; and you must listen respectfully to all they say: but even
if they should say, which I am sure they never would, 'That cannot 
exist. That is contrary to Nature', you must wait a little and see 
for perhaps even they may be wrong.
Charles Kingsley (The Water Babies)'
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1.1. CYTOCHROME P-450
1.1.1. Historical
Microsomes are a heterogenous mixture of fragmented 
endoplasmic reticulum, golgi bodies, fragments of plasma membrane and 
mitochondria and have been operationally defined (Siekevitz, 1965) as 
"the high speed pellet (from 100,000 g to 250,000 g for 60 to 120 min) 
resulting when the supernatant fluid from the mitochondrial fraction is 
sedimented". Biochemical studies on microsomal electron transfer reactions 
began as early as 1949 when Hogeboom demonstrated that microsomes could 
mediate the transfer of electrons from NADH to exogenous cytochrome c.
The work of Strittmatter and co-workers (1952) resulted in the 
characterization of cytochrome bs. During their studies on electron 
transport Klingenberg (1958) and Garfinkel (1958) independently 
discovered a microsomal carbon monoxide binding pigment; subsequently 
detailed studies by Omura and Sato (1962; 1964a, b) indicated that this 
pigment was a haem-containing protein of the b type. It was from this 
work that cytochrome P-450 derived its name since it combines in the 
reduced state with carbon monoxide to show a single Soret absorption 
maximum at 450 nm.
Pharmacological studies with hepatic microsomes were 
initiated by Axelrod (1954), who observed the demethylation of 
sympathomimetic amines and the oxidative deamination of amphetamine to 
phenylacetone and ammonia. This provided the first demonstration of a 
requirement for oxygen and NADPH during the microsomal oxidation of 
foreign compounds. Since this time the absolute requirements for these 
cofactors has been realized and the microsomal enzymes have been termed 
mixed function oxidases (Mason, 1957) or monooxygenases (Hayaishi, 1962).
The initial demonstration that cytochrome P-450 was linked 
to the mixed function oxidation of foreign compounds and some endogenous 
steroids was by Estabrook, Cooper and Rosenthal (1963). The photochemical 
action spectrum for steroid C-21 hydroxylation obtained by these authors 
indicated that light around 450 nm yielded the most efficient reversal of 
carbon monoxide inhibition. Hence by the middle of the 1960's it was 
generally accepted that cytochrome P-450 was of prime importance in the 
metabolism of foreign compounds and endogenous steroids.
The versatility of the microsomal mixed function oxygenase 
system(s) is unique, and in recent years it has been shown to catalyse 
such diverse reactions as the oxidation of alkanes and aromatics, the 
epoxidation of alkanes and polycyclic hydrocarbons, the dealkylation of 
substituted amines, the N-oxidation of amines, the dealkylation of 
aromatic ethers, and the oxidative cleavage of organic thiophosphate esters 
(Parke, 1969). Evidence also exists for the participation of microsomal 
mixed function oxygenase in nitro- and azo-reduction as well as in the 
reductive cleavage of halogenated alkanes (Carlson and Dubois, 1970; 
Mitchard, 1971).
1.1.2. Occurrence
Cytochrome P-450 is a truly ubiquitous enzyme and has been 
found in many diverse organisms, including mammals, birds, fish, yeasts, 
bacteria and plants. In mammals it has been identified in numerous 
tissues including liver, kidney, adrenals, pancreas, pituitary, lung, 
small intestine and skin. In mammalian tissue cytochrome P-450 is 
generally localized in the endoplasmic reticulum, although it is also 
found in the mitochondria of steroidiogenic tissues. The wide distribution 
of cytochrome P-450 has recently been reviewed by Wickramasinghe (1975).
1.1.3. Purification and Stability
As previously mentioned reduced cytochrome P-450 reacts with 
carbon monoxide resulting in a maximal light absorption at 450 nm. The 
treatment of microsomes with various agents (e.g. phospholipases or 
detergents, Omura and Sato, 1964a, b; ureas and alcohols, Ichikaura and 
Yamano, 1967) produces a cytochrome which when combined with carbon 
monoxide shows an absorption maximum at 420 nm. This haemoprotein has 
been termed cytochrome P-420 (Omura and Sato, 1964a, b) and is inactive 
in oxidation reactions. The denaturation of cytochrome P-450 by some 
detergents may be reversed by the addition of polyols or reduced 
glutathione, but the effect of other agents such as urea, sodium 
dodecyl sulphate and the guanidinium salts is apparently irreversible 
(Ichikaura and Yamano, 1967b).
• In addition to the denaturation of cytochrome P-450 to 
cytochrome P-420, the destruction of the active haemoprotein may occur.
Many compounds such as carbon disulphide (Bond and'De Matteis, 1969), 2-allyl- 
2-isopropyl-acetamide (De Matteis, 1973), allyl-containing barbiturates 
(Levin et al., 1973) and phenylhydrazine (Jonen et al., 1975) destroy 
cytochrome P-450 both in vivo and in vitro with the concomitant formation 
of carbon monoxide and unidentified green pigments. Lipid peroxidation 
(Jacobson et al., 1973; Levin et al., 1973) and microsomal haem oxygenase 
reactions (Tenhunen et al., 1972) also result in the destruction of 
cytochrome P-450.
The instability of cytochrome P-450 in the presence of 
detergents has posed problems in its purification. Since it is a membrane- 
bound enzyme it is first necessary to solubilize it. This has been 
successfully achieved over the last few years, notably by the efforts of 
Coon, Lu and their co-workers. An excellent review on the solubilization 
and resolution of the enzyme system has recently appeared (Lu and Levin,
1974). Because of the difficulty of purification the presence of
residual detergent and the loss of membrane integrity, most studies to 
date on hepatic microsomal cytochrome P-450 have been made with untreated 
microsomal preparations.
1.1.4. Substrate-induced Spectral Changes
The interactions of exogenous ligands with cytochrome P-450 
has been studied most extensively using the technique of difference 
spectrophotometry. The difference spectrum obtained from this technique 
is the result when the absorbance of the contents of the reference 
cuvette is subtracted from the absorbance of the contents of the sample 
cuvette.
Following the observation of Narasimhulu, Cooper and 
Rosenthal (1965) that spectral changes occur when steroids are added to 
adrenocortical microsomes; Remmer et al., (1966), Iraai and Sato (1966) and 
Schenkman, Remmer and Estabrook (1967) reported similar observations after 
the addition of drug substrate to liver microsomal suspensions. These 
difference spectra have been classified according to their maxima and 
minima into three distinct types - Type I, Type II and Reverse Type I 
(formally modified Type II). In the microsomal difference spectrum the 
Type I is typified by a peak at 380-395 nm and a trough at 415-425 nm, 
the Type II spectral change has a maximum at 425-435 nm and a minimum at 
395-405 nm. The reverse Type I (Type RI) change is the mirror image of 
the Type I spectral change, exhibiting a trough at 380-395 nm and a peak 
at 415-425 nm. Fig. 1.1 summarizes these various substrate-elicited spectral 
changes.
Schenkman et al., (1967) suggested that these spectral 
changes are the optical manifestation of a substrate-cytochrome P-450 
interaction and indicated a method for estimating the apparent binding 
affinity of the substrate. They obtained Kg (spectral dissociation 
constant) values for a variety of compounds by plotting on a double
FIGURE 1.1.
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reciprocal graph the magnitude of the spectral change against the 
substrate concentration. The Kg value by definition is the concentration 
of substrate which when added to a microsomal suspension results in half 
of the maximal spectral change. These workers found a good correlation 
between the Kg value for binding and the Km value for monooxygenation of 
some compounds. However this correlation is not universal and is 
dependent on many factors such as the substrate employed, the species 
and the degree of induction.
The Type I spectral change is elicited by a wide variety of 
compounds (e.g. barbiturates, fatty acids, hydrocarbons, steroids and 
carbamates), the only common factor is their high lipid and low water 
solubilities. Kitagawa, Kitada and Horie (1972) and Al-Gailany (1975) 
have shown a direct correlation between Ks value and lipid solubility, 
however the suggestion that these two parameters are intimately related 
has been challenged by Jansson et al., (1972) from results obtained 
using a homologous series of barbiturates. However, as discussed by 
Al-Gailany (1975) if their data is replotted as log Ks against log P 
(log octanol-water partition coefficient) a good correlation can be 
obtained.
Schenkman and Sato (1968) have suggested that the Type I 
interaction is not directly with the haem of cytochrome P-450 but that 
the added ligand reacts with a hydrophobic moiety of the apoprotein. This 
view is supported by findings that the Type I binding site is destroyed 
after extraction of the microsomal phospholipids (Chaplin and Mannering, 
1970; Leibman and Estabrook, 1971). -
Compounds which produce Type II binding spectra, such as 
primary amines, are always nucleophilic in.nature. Schenkman and co-workers 
(Schenkman et al., 1967; Schenkman, 1970) have suggested that the Type II 
interaction is due to the formation of a ferrihaemochromogen caused'by
the direct interaction of a basic nitrogenous ligand with the haem iron 
of cytochrome P-450. The observation that compounds which elicit the 
Type II spectrum are not generally substrates of the cytochrome P-450 
monooxygenase tends to support this view. The Type II interaction is 
competitive with carbon monoxide (Schenkman et al., 1973) and is thus, 
in all probability, competitive with oxygen. Hence the formation of a 
ferrihaemochromogen and the observation of a Type II spectrum is indicative 
of a metabolically non-productive complex. Aniline (a Type II compound) is 
metabolized; however this is presumably because it also binds to cytochrome 
P-450 in the Type I mode (Schenkman, 1970).
The reverse Type I (Type RI) spectral change has frequently 
been confused with the Type II interaction because of their similar 
spectrophotometric appearances (Whysner, Ramseyer and Harding, 1969), but 
Type RI compounds, unlike Type II compounds, do not compete with carbon 
monoxide for binding to reduced cytochrome P-450, (Schenkman et al.,
1973; Dickins et al., 1975). Schenkman et al., (1972;1973) suggested 
that the Type RI spectral change is caused by the displacement of 
endogenous Type I substrates from the microsomes. However recent work 
by Vore et al., (1974) using acetone extracted microsomes and Al-Gailany 
(1975) using fluorescent probes indicates that the Type RI spectral change 
is due to compounds binding to a specific site and not simply to the 
displacement of endogenous compounds from the Type I site. Reverse Type I 
compounds are as diverse as Type I compounds, ranging from phenacetin 
(Schenkman, 1972) through the short chain monohydric alcohols to the
2-substituted benzimidazoles (Dickins et al., 1975).
1.1.5. Theoretical Interpretation of Spectral Changes
The valence 3d orbitals of iron in an octahedral molecular 
environment are split into two sub-levels (Fig. 1.2a). The more energetic 
is called eg and includes the two d orbitals dx2-y2 and dz2, which interact
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strongly in o_ bonding with ligands. Because of their spatial orientation, 
the other three d orbitals (d^^dy^d^y) in the lower energy (t2g) suk“ 
level can only participate in tt interactions with ligands. The orbitals 
of the tgg and the eg sub-levels are termed non-bonding and anti-bonding 
respectively. This splitting of levels is termed octahedral LF splitting 
and in iron complexes is larger for the Fe3+ than the Fe2+, hence the 
tendency towards a low spin state is greater in the oxidized haemoprotein. 
The presence of ligands alters the electronic configuration of the ground 
states to an extent which depends on the ligand field strength. For 
example in strong ligand fields (e.g. CN”) the electrons of the 
sub-levels tend to be transfered to the sub-level leading to the 
formation of a low spin complex. The converse situation applies in the 
presence of a weak ligand field (e.g. H£0) resulting in the production of 
a high spin complex. This principle is illustrated in Fig. 1.2b.
In cytochrome P-450 four of the ligands are basic nitrogen 
atoms of the tetrapyrrole ring system. The fifth and sixth ligands of 
the cytochrome P-450 iron appear to be the mercaptide group of a cysteine 
residue (Mason, North and Vanneste, 1965; Peisach, Stern and Blumberg,
1973) and the imidazole nitrogen of a histidine residue (Jefcoate and 
Gay lor, 1969). Since the iron of cytochrome P-450 is in a heterogenous 
ligand field distortion of the octahedral environment occurs. This 
assymetry may in turn lead to further splitting of the 3d orbitals.
The spectral behaviour of oxidized cytochrome P-450 on 
the addition of substrate is probably attributable to changes in the haem- 
ligand group distances and/or composition of the coordination complex, and 
hence an alteration in the spin state. In general the Soret band of high 
spin haemoproteins is at 390 nm and that of low spin haemoproteins at 
420 nm. The appearance of a Type I binding spectrum (increase in 
absorbance at 390 nm and decrease at 420 nm) has been correlated with the 
conversion of low spin cytochrome P-450 to the high spin form (Waterman,
Ullrich and Estabrook, 1973). It is thought that the increase of high spin 
character observed upon the addition of a type I substrate to oxidized 
cytochrome P-450 reflects a conformationally induced change in which the 
distance between the iron and the ligand in the position opposite the 
mercaptide group is altered (Jefcoate and Gaylor, 1969; Hill, Roder and 
Williams, 1970; Tsai et al., 1970). However Type II compounds are 
thought to become bound directly to the iron through displacement of the 
coordinated protein group in the position opposite the cysteine residue 
to yield a complex with enhanced low spin character.
The binding of compounds such as carbon monoxide to reduced 
cytochrome P-450 also results in the displacement of the non-mercaptide 
ligand (Peisach et al., 1973). However, it is the belief of these authors 
that ethylisocyanide, which binds to reduced cytochrome P-450 resulting 
in the appearance of Soret bands at 430 and 455 nm- (Imai and Sato, 1966) , 
displaces both the mercaptide and non-mercaptide ligands.
1.1.6. Mechanism of Mixed Function Oxidation
Estabrook et al. (1972) proposed a generalized scheme 
describing a cyclic reaction during mixed function oxygenation (Fig. 1.3).
Initially an organic substrate (RH) binds to the apoprotein
moiety of the low spin oxidized (Fe3+) form of the haemoprotein, producing
a high spin ferricytochrome P-450-substrate complex (Fe3+-RH). This is
observed by the formation of a Type I binding spectrum. The haemoprotein-
substrate complex undergoes a one electron reduction (accepting an electron
via the flavoprotein NADPH-cytochrome P-450 reductase from NADPH) to the
ferrous haemoprotein-substrate complex. This complex can now react with
molecular oxygen to produce a ternary complex of cytochrome P-450, substrate
and oxygen (Fe2+-RH). This ternary complex has been identified by 
02
FIGURE 1.3.
A Generalized Scheme for Cytochrome P-450 mediated Monooxygenation
(from Estabrook et al., 1972)
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spectrophotometry; it has an absorbance maximum at 440 nm and has been termed 
oxycytochrome P-450 (Estabrook et al./ 1971; Illing, Kunke and Netter,
1974). The oxycytochrome P-450 complex undergoes a further one electron 
reduction forming a hereto unidentified complex. This electron addition 
may be mediated by cytochrome bs and aided by the presence of NADH. Recent 
work (Lu et al., 1974) indicates that the synergistic effect of NADH and 
cytochrome bs on mixed function oxidation depends on the substrate and 
the type of cytochrome P-450 under study. After this second reduction a 
further intramolecular rearrangement occurs and one atom of oxygen is 
inserted into the substrate together with the elimination of water, 
leaving the enzyme-product complex (Fe^+ SOH). Finally the haemoprotein- 
product complex dissociates into free enzyme and product, allowing the 
cycle to be repeated. Discussion on the structure of the "active oxygen" 
species involved will be found later.
1.1.7. Multiplicity and Induction
The stimulatory effect of foreign compounds upon liver 
microsomal mixed function oxygenation was first observed by Brown,
Miller and Miller (1953) during studies of dietary factors influencing 
the demethylation of aminoazodyes. Further studies by these workers 
indicated that polycyclic aromatic hydrocarbons rapidly caused an increase 
in the activity of hepatic microsomal monooxygenation. The stimulating 
effect of barbiturates on drug metabolism was first observed independently 
by Remmer (1958;1959) and Conney and Burns (1959;1960).
Stimulating agents which are active in vivo have been termed 
inducers, and may be broadly classified into two main classes, 
exemplified by the barbiturates (e.g. phenobarbitone) and the polycyclic 
hydrocarbons (e.g. 20-methylcholanthrene) . Inducers of the phenobarbitone 
type induce a wide spectrum of microsomal oxygenative metabolic pathways, 
whereas the 20-methylcholanthrene type is more specific in its action.
Conney (1967) reviews the inducing specificity of various stimulating agents. 
Recent observations suggest that there may be more than two groups of 
inducing agents; the spectrum of enzymic pathways stimulated by chlorinated 
biphenyls or pregnenolone-16a-carbonitrile differs from that stimulated by 
phenobarbitone or 20-methylcholanthrene, (Alvares et al., 1973).
The mechanisms of induction of mixed function oxidation 
by foreign compounds are complex and poorly understood. However induction 
by foreign compounds appears to be dependent on the de novo synthesis of 
drug metabolizing enzyme systems; since interference with DNA-directed RNA 
synthesis or protein synthesis by actinomycin D or cycloheximide, 
respectively, prevents the drug related increase in mixed function 
oxygenation (Von Der Decken and Hultin, 1960; Gelboin and Blackburn, 1963; 
Conney and Burns, 1962; Conney and Gilman, 1963).
Inducers may modify gene activation processes, for example, 
increase aggregate RNA polymerase activity, increase chromatin template 
activity or increase the template activity of nuclear RNA (Gelboin,
1964; Gelboin and Sokoloff, 1964; Bresnick, 1966). It has been 
suggested that inducers may affect the initiation of protein synthesis 
(Heywood, 1970) and even translation control factors (Lanclos and 
Bresnick, 1973). As well as increased RNA and protein synthesis the 
stabilization and decreased degradation of these components has been 
implicated in the induction of drug metabolizing activity, (Shuster and 
Jick, 1966a,b; Seifert and Vacha, 1970; Louis-Ferdinand and Fuller, 1972; 
Pousada and Lechner, 1972).
In summary it is likely that the induction of mixed 
function oxygenation is due to both increased synthesis and decreased 
degradation of endoplasmic reticulum components as well as alteration 
of translation events. However the primary event in the induction 
phenomenon has yet to be identified.
Inducing agents of both the 20-methylcholanthrene and the 
phenobarbitone type increase the total amount of cytochrome (s) P-450, 
however the polycyclic hydrocarbons induce an aberrant haemoprotein.
The carbon monoxide complex with this cytochrome has its maximal light 
absorption at 448 nm (Hildenbrandt, Remmer and Estabrook, 1968; Alvares 
et al., 1967). This cytochrome has also been called cytochrome Pi-450.
Multiple forms of cytochrome P-450 have been identified 
in hepatic microsomes from normal (untreated) rats and rabbits. Recently 
Comai and Gaylor (1973), using cyanide and n-octylamine as ligands, have 
demonstrated three spectrally distinct forms of cytochrome P-450 in 
rat hepatic microsomes. These authors have named these cytochromes forms 
I, II and III. Form I is preferentially induced by ethanol, form II by 
phenobarbitone and form III by 20-methylcholanthrene. The existence of 
spectrally and catalytically distinguishable cytochromes P-450 has been 
confirmed by Werringloer and Estabrook (1975). These workers defined at 
least four distinct pools of cytochrome P-450, in control rats, on the 
basis of their reactivities with metyrapone, carbon monoxide, ethyl 
isocyanide and benzphetamine.
Experiments by Lu et al. (1972) using a solubilized, 
reconstituted system, indicated that the specificity of microsomal mixed 
function oxygenation resided within the cytochrome P-450 fraction. 
Recently the significance of this work has been realized. Haugen,
Van der Hoeven and Coon (1975) have isolated at least four (and possibly 
seven) distinct forms of cytochrome P-450 from control rabbits by sodium 
dodecyl sulphate polyacrylamide gel electrophoresis. Induction by
3-naphthoflavone or phenobarbitone increased each of these forms to 
varying extents.
Hence it appears that cytochrome P-450 is not a single 
highly unspecific enzyme, but it is a heterogeneous mixture of several 
enzymes each having its own range of substrate specificities.
1.1.8. Inhibition of Monooxygenation
Inhibition of cytochrome P-450 mediated monooxygenation 
reactions may arise by diverse mechanisms. These are summarized in 
Fig. 1.4 (Netter, 1973) . I shall briefly discuss the mode of action of 
some of the more common inhibitors.
Carbon Monoxide
This is the classical inhibitor of cytochrome P-450 
mediated reactions. It binds to the Fe2+ form of the cytochrome P-450 
haem thereby inhibiting the activation of oxygen. Carbon monoxide is 
of particular value in determining the participation of cytochrome P-450 
in a particular drug oxygenation reaction.
Sulphydryl Reagents
Mercurials such as mersalyl (Franklin and Estabrook,
1971), p-chloromercuribenzoate (Orrenius, 1965; Kampffmeyer and Kiese, 
1963;1964; Illing and Netter, 1975) and alkylating agents such as 
N-ethylmaleimide (Kampffmeyer and Kiese, 1963;1964; Illing and Netter,
1975) and iodoacetamide (Illing and Netter, 1975) have been used as 
inhibitors of many different metabolic transformations mediated by the 
cytochrome P-450 mixed function oxygenase system. These compounds have 
been shown to have multiple sites of action within the mixed function 
oxygenase complex. For example, p-chloromercuribenzoate appears to 
denature P-450 and to inhibit NADPH-cytochrome P-450 reductase, oxygen 
utilization and the subsequent formation of the ternary oxycytochrome 
P-450 complex (Illing and Netter, 1975).
FIGURE 1.4.
Mechanisms of Inhibition of Monooxygenation
(from Netter, 1973)
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Metyrapone (I) is a potent inhibitor of monooxygenation at 
yM concentrations. The mechanism of inhibition by metyrapone has been 
reported as both competitive (Kahl, Magnussen and Netter, 1969) and non- 
competitive (Hildebrandt, 1971). Metyrapone binds to the haem of 
cytochrome P-450 in the oxidized state producing a Type II binding 
spectrum. However with reduced cytochrome P-450 a single Soret band at 
446 nm is apparent (Hildebrandt, Leibman and Estabrook, 1969). Hence 
the mode of inhibition due to metyrapone is probably ascribable to the 
prevention of oxygen activation. Kahl and Netter (1970) originally 
reported the complete absence of oxidative metabolism of metyrapone, 
however recently Kahl et al., (1974) demonstrated that a small proportion 
of metyrapone was metabolized oxidatively via the cytochrome P-450 
system. Thus this observation may explain the sometimes competitive 
nature of inhibition by metyrapone.
SKF-525A ($-diethylaminoethyl-diphenyl-propyt acetate hydrochloride)
©
Cl
(II)
SKF-525A (II) has been used extensively as an inhibitor of 
monooxygenation both 'in vivo and in vitro. In vivo a biphasic response
©  CH2CH3
CH 3CH2CH2C-C-O-CH2.CH2NH
\ch2ch3
is observed. Initially inhibition of cytochrome P-450 mediated reactions 
occurs, but about 12 hours later induction (de novo synthesis) of the 
enzyme system is observed (Kato, Chiesard and Vassanelli, 1964).
The type of inhibition due to SKF-525A is complex; competitive, 
non-competitive and mixed inhibition kinetics have been observed (Anders 
and Mannering, 1968; Ikeda et al., 1968). Jenner and Netter (1972) have 
indicated that the nature of the inhibition due to SKF-525A can be 
dependent upon the solvent from which recrystallization was effected.
SKF-525A exhibits a Type I binding spectrum and is metabolized 
via cytochrome P-450 (Anders, Alvares and Mannering, 1966) , hence some 
degree of competitive inhibition is likely. However since the for 
inhibition and the K^ j for metabolism of SKF-525A are different (Anders,
1971) simple competitive inhibition is not the sole mode of action. In 
these experiments the was lower than expected and decreased with 
incubation time. This possibly indicates that a metabolite of SKF-525A, 
with a higher affinity for cytochrome P-450, was being formed. During the 
metabolism of SKF-525A in vitro the generation of an absorbance maximum 
at 455 nm can be observed (Schenkman, Wilson and Cinti, 1972). The 
appearance of this Soret band has been attributed to the formation of a 
complex between reduced cytochrome P-450 and an SKF-525A intermediate 
or metabolite. It is likely that the production of this complex results 
in the observation of non-competitive inhibition kinetics.
1-Substituted Imidazoles
Recently compounds of this class have been shown to be 
potent inhibitors of monooxygenation (Leibman and Ortiz, 1973; Palmer 
and Cawthome, 1974; Wilkinson et al., 1974). The most effective 
inhibitor of mixed function oxygenation in rat hepatic microsomes known is 
1-(2-isopropylphenyl) imidazole (III).
(Ill)
This compound is between 10 and 100 times more potent than 
metyrapone or SKF-525A.
The methylenedioxyphenyl compounds are another class of 
cytochrome P-450 inhibitors. These have been utilized commercially 
as insecticide synergists and their mode(s) of action will be the 
subject of later discussion.
1.2. METHYLENEDIOXYPHENYL COMPOUNDS (1,3-BENZ0DI0X0LES)
1.2.1. Occurrence
Methylenedioxyphenyl compounds (MDP) are found widely 
distributed in nature, being encountered as secondary metabolites of 
plants. Compounds of this class have been isolated from nutmeg, parsley, 
parsnip, mint (Weil, 1965), camphor oil, sassafras oil, black pepper, 
carrots (Fishbein and Falk, 1969) and also detected in cigarette 
smoke (Schmeitz et al., 1966).
1.2.2. Toxicity of Methylenedioxyphenyl Compounds
Most MDP compounds are of inherently low acute toxicity.
However cases of acute safrole poisoning due to ingestion of sassafras
oil (80% safrole) have been reported (Craig, 1953). Safrole has also
been shown to be a weak hepatocarcinogen in rats (Long et al., 1967) 
causing hepatic carcinoma and adenoma. This work, the results of a 
U.S. Food and Drug Administration project, led to the prohibition of 
safrole as a food additive. Until this time it had extensive use
particularly as a flavouring agent in soft drinks such as root beer 
(Jacobs, 1958) and as a natural ingredient of sassafras tea (Power 
and Kleber, 1896).
Many of the acute properties of MDP compounds arise from 
their inhibition of mixed function oxygenation. For example piperonyl 
butoxide has been shown to increase the acute toxicity of freons 112 and 
113, griseofulvin and benzpyrene in mice (Falk and Kotin, 1969; Epstein 
e t a l ., 1967a). Piperonyl butoxide also increased the acute toxicity of 
0-[3-chloro-4-methyl-umbilliferone]-0,0-diethyl phosphorothioate 
(Coumaphos) in mice. Toxicities arising from metabolites are frequently 
decreased by piperonyl butoxide treatment, for example piperonyl 
butoxide increased parathion toxicity but it decreased toxicity due to 
methyl parathion (Kamienski and Murphy, 1971). MDP compounds have 
also been implicated as cocarcinogens. Epstein et- al., (1967b) indicated 
that piperonyl butoxide synergized the production of hepatic tumours 
by Freon 112 and 113.
1.2.3. Insecticide Synergism and Inhibition of Mixed Function
Oxidation by Methylenedioxyphenyl Compounds
The first observation of synergistic activity between an
insecticide and a MDP compound was by Eagleson (1942) who demonstrated
the potentiation of pyrethrum toxicity in houseflies by sesame oil
(from the seeds of Sesamum irid'Lcim) . Subsequently it was shown that
c.
sesamin and sesamolin are the active synergists of sesame oil. It is 
interesting to note that sesamin is also a natural component of pyrethrum 
extract and as such coexists with the insecticidal pyrethrins and 
cinerins (Doskatch and El-Feraly, 1969). The synthetic MDP synergists 
currently in use are prepared from the natural product safrole (4-ally1-
1.2-methylenedioxybenzene), by converting it to dihydrosafrole (4-propyl-
1.2-methylenedioxybenzene) , isosafrole (4-propenyl-l,2-methylenedioxybenzene) 
and other intermediates useful in the preparation of the desired MDP
product. The most frequently used MDP synergists are sulphoxide, 
propylisome, tropital and piperonyl butoxide. The annual consumption 
of piperonyl butoxide in the United States is presently over 800,000 
lb per year.
The MDP synergists have a broad spectrum of action, 
potentiating the insecticidal activity of pyrethroids, organophosphates, 
rotenoids, chlorinated hydrocarbons and carbamates. The observations 
that these compounds are all substrates for the microsomal mixed 
function oxygenase system led Sun and Johnson (1960) to postulate 
that MDP synergism is due to inhibition of the metabolism of the 
insecticidal compound. Hodgson and Casida (1960;1961) demonstrated 
the inhibition of the oxidative metabolism of N,N-dimethyl-p-nitro- 
phenyl carbamate and its diethyl analogue by piperonyl butoxide and 
sesamex in rat liver microsomes. Since then many investigators have 
demonstrated the inhibition of mixed function oxygenation by MDP 
compounds. A comprehensive review on the mixed function oxygenase 
involvement in synergist action has appeared (Casida, 1970).
Descriptions of the kinetic mechanism of MDP compound 
inhibition of mixed function oxygenation have been conflicting. Casida 
et al. (1966) proposed an alternate substrate hypothesis on the basis 
of MDP compound metabolism V'ia mixed function oxygenation. However the 
type of inhibition has been variously reported to be competitive, 
partially competitive, curvilinear and non-competitive (Lewis, Wilkinson 
and Ray, 1967; Anders, 1968; Brooks and Harrison, 1969; Fujii et al., 
1970). These apparent anomalies have been explained by Franklin (1972) 
and Philpot and Hodgson (1972) as being due to a dual inhibitory effect, 
involving both competitive inhibition due to competition between the 
substrate and the MDP inhibitor for metabolism, and non-competitive 
inhibition due to the formation of a very stable complex between a 
MDP metabolite and reduced cytochrome P-450. Hence inhibition kinetics
initially appear competitive; but once metabolism of the MDP inhibitor 
occurs with the concomitant formation of the metabolite-reduced cytochrome 
P-450 complex, then the inhibiting kinetics are of a noncompetitive nature
The formation of a MDP metabolite-cytochrome P-450 complex 
can be observed spectrophotometrically in vitro. When microsomes, 
supplemented with NADPH, are incubated in the presence of a MDP compound 
such as safrole characteristic absorption maxima in the Soret region may 
be observed. Generally the absorption maxima are at 427 and 455 nm (Franklin, 
1971; Philpot and Hodgson, 1971; Elcombe et al., 1975). Further studies 
have provided indirect evidence that the formation of this characteristic 
absorption spectrum is indeed due to the formation of a MDP metabolite- 
cytochrome P-450 complex. However this will be discussed in greater 
detail later.
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Matthews, Skrinjaric-Spoljar and Casida (1970), using 
microsomes obtained from mice pretreated with MDP compounds, demonstrated 
that an apparent decrease of cytochrome P-450 levels accompanied the 
reduction of hexobarbitone and aniline metabolism. Subsequently an 
apparent reduction of cytochrome P-450 content by piperonyl butoxide 
was observed in vitro (Philpot and Hodgson, 1971). This observation 
provided an explanation of the apparent decrease in cytochrome P-450 
observed by Matthews et al. (1970) since the combination of carbon 
monoxide with reduced cytochrome P-450 is employed in the assay of this 
haemoprotein (Omura and Sato, 1964a). Parke and Rahman (1971) have 
indicated that the presumed MDP metabolite-cytochrome P-450 complex 
may also be obtained in vivo.
The present study was initiated to investigate further the 
in vivo and in vitro interactions of MDP compounds (particularly safrole 
and isosafrole) with hepatic microsomal cytochrome P-450.
1.2.4. Induction of Mixed Function Oxygenation by MDP Compounds 
Short term treatment (less than 24 hours) of animals with MDP
compounds results in the inhibition of mixed function oxygenation. However
after longer periods induction of oxygenation occurs (Jaffe et al., 1968; 
v / v
Skrinjaric-Spoljar et al., 1971; Wagstaff and Short, 1971; Gray et al.,
1972; Lake, 1974). Studies of this biphasic response are not extensive 
either in species or compounds examined, however it appears to be a 
general phenomenon. Hodgson and Philpot (1974) have recently reviewed 
this topic.
Few investigators have examined the characteristics of the 
induced cytochrome. Lotlikar and Wasserman (1972) indicated that safrole 
and isosafrole, in common with 20-methylcholanthrene, induced the 3- and 
5-hydrOxylation of acetamidofluorene to a greater extent than the N- 
hydroxylation reaction. This effect was prevented by the prior treatment 
of the animals with ethionine to inhibit protein synthesis. Lake et al, 
(1973) have demonstrated that in both hepatic and extrahepatic tissue 
the 'pattern of induction' (with respect to substrates) due to MDP 
compounds is similar to that obtained with 20-methylcholanthrene.
The present work attempts to examine the properties of the 
cytochrome(s) P-450 induced by MDP compounds.
1.2.5. Metabolism of Methylenedioxyphenyl Compounds
Four principle oxidative routes of metabolism have been 
shown to exist for MDP compounds. These in order of importance are 
oxidative cleavage of the methylene bridge (demethylenation) with 
concomitant formation Of carbon dioxide and the corresponding catechol, 
the modification of side-chains and finally the oxidation of side-chains 
to piperonylic acid and its derivatives. Furthermore conjugation of 
metabolites may occur. The complexity of MDP compound metabolism is well
illustrated by the metabolic pattern for safrole, Fig. 1.5 (Stillwell, 
et al., 1974).
Similarly complex metabolic pathways have been demonstrated 
for piperonyl butoxide (Fishbein et al., 1967; Kamienski and Casida,
1970). Fishbein et al. (1969) detected at least 28 urinary and biliary 
metabolites of piperonyl butoxide in mice. Few other detailed studies 
of the metabolism of MDP compounds have appeared but it appears likely 
that most compounds of this class undergo similar metabolic transformations. 
The importance of a particular pathway may vary greatly from species to 
species. For example mammals are more efficient at demethylenation than 
are insects (Casida et al., 1966; Esaac and Casida, 1969).
FIGURE 1.6.
Proposed Metabolism of Safrole in Rat and Guinea Pig
(from Stillwell et al., 1974)
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2.1. Chemicals
NADH, NADP+, NADPH, glucose-6-phosphate (disodium salt),
glucose-6-phosphate dehydrogenase, glutamate dehydrogenase, a-oxoglutarate
R(mono-sodium salt) and Tris (Trizma base) were all purchased from Sigma 
London Chemical Co. Ltd. (Surrey, England).
il/j'il^ -Dimethylformamide (puriss) and n-octylamine (puriss) 
were obtained from Koch-Light Laboratories Ltd. (Bucks., England). Cumene 
hydroperoxide was supplied by Matheson, Glemen and Bell (USA).
Safrole was purchased from Hopkin and Williams Ltd. (England) 
and isosafrole was obtained from Eastman Kodak Co. (Kirkby, England). All 
other methylenedioxyphenyl compounds were supplied by the Aldrich Chemical 
Co. Ltd. (Middlesex, England), except for sesamex,. sulphoxide and piperonyl 
butoxide which were kindly donated by Mr. G. Powll of the Wellcome Research 
Laboratories (Berkhamsted).
[W^C]-Isosafrole (5 mCi mmol"1) was purchased from the 
Radiochemical Centre Ltd. (Amersham, England) and was 99% radiochemically 
pure.
Carbon monoxide and nitrogen were purchased from the 
British Oxygen Co. Ltd. (Surrey, England). All other reagents were of 
the highest purity commercially available.
2.2. Animals
Male albino Wistar (Canterbury Ash) rats, obtained from Charles 
River (Margate, Kent), were used throughout this study. Rats were initially 
70-80 g for feeding experiments, otherwise a weight range of 150-200 g was 
used. All rats were caged in groups of six, in wire bottomed cages, over 
sawdust (sterilized, dust free) obtained from Lee and Son Limited. The 
animals were allowed food (Heygates rat pellets) and water ad libitum. A 
twelve hour light/dark cycle was in use (0070-1900 light); animals were 
always killed and dosed at the same time of day (9.30 a.m.).
2.2.1. Pretreatment of Rats
Safrole and isosafrole
These compounds were either administered in the diet or by 
intraperitoneal (i.p.) injection.
Dietary compounds (0.5-1.0%'w/w) were mixed with normal 
diet (Heywoods rats pellets) which had previously been powdered. Animals 
were allowed food and water ad libitum.
When administered by i.p. injection safrole and isosafrole 
(150 mg kg-1) were first dissolved in corn-oil to a concentration such 
that 0.2 ml corn-oil contained the required amount of compound.
Phenobarbitone
Phenobarbitone (sodium salt) was dissolved in 0.9% (w/v)
saline. For induction purposes 0.5 ml of solution was administered i.p.
(80 mg kg”1) once daily for three consecutive days. The animal was 
killed 24 hours after the last injection.
20-MethyIcholanthrene
This was administered as a solution in corn-oil, such 
that 0.5 ml of solution contained the required amount. For induction 
studies a single dose (30 mg kg-1) was given, and the animal sacrificed 
24 hours afterwards.
2.2.2. Metabolism Cages
Radiolabel studies were carried out in all-glass metabolism 
cages with facilities for the collection of expired carbon dioxide, urine 
and faeces. Expired carbon dioxide was absorbed into a solution of
ethanolamine (2 vol.) and ethoxyethanol (1 vol.) and the radioactivity
measured using tT21 scintillant as described later.
2.3.1. Preparation of Microsomes
Rats were killed by cervical dislocation and the livers 
rapidly excised into ice-cold 1.15% (w/v) KC1 and washed well to remove 
adhering haemoglobin. The livers were blotted dry on filter paper and 
then weighed. All subsequent operations were carried out at 0 -4°. The 
livers were scissor-chopped and homogenized in 4 volumes (w/v) of ice-cold 
1.15% (w/v) KCl using a motor driven Potter-Elvehjem-type glass-Teflon 
homogenizer (6 complete strokes). The liver homogenate was centrifuged 
in 50 ml polycarbonate Oakridge tubes (M.S.E. Limited) at
15,000 gav (13,500 rev. min-1) for 15 min using a 8 x 50 ml aluminium 
angle head rotor in a M.S.E. H.S.18. refrigerated centrifuge. The 
supernatant was carefully decanted and recentrifuged at 75,000 gav 
(30,000 rev. min-1) for 90 min in a M.S.E. S.S.40 centrifuge. The 
supernatant obtained was discarded and the top of the crude microsomal 
pellet rinsed with ice-cold 1.15% (w/v) KCl. The pellet was resuspended 
in 1.15% (w/v) KCl using a Potter-Elvenhjem homogenizer (2 strokes) and
the resultant suspension recentrifuged at 75,000 gav for 90 min. The 
washed microsomal pellet so obtained was finally resuspended in 20 mM 
Tris-HCl buffer (pH 7.4) containing 250 mM sucrose and 5.4 mM EDTA 
(Netter, 1960) to a concentration equivalent to about 1-1.5 g liver per 
ml (approximately 20-30 mg microsomal protein per ml). The microsomal 
suspension was stored in 2 ml aliquots in conical polycarbonate sample 
cups (L.I.P. Equipment and Services Limited) and stored at -20°. All 
microsomes were used within 2 weeks of preparation. Fresh microsomal 
preparations were used in some parts of the present study, and no differences 
were detected between the fresh and stored,microsomal suspensions.
Microsomes were obtained from the pooled livers of 6 rats 
unless otherwise stated.
When small volumes of homogenates were used the post-15,000 gav 
centrifugations were carried out using a 10 x 10 ml Titanium angle head 
rotor at 300,000 gav (65,000 rev. min-1) for 20 min in a M.S.E. S.S.65 
centrifuge.
2.3.2. Subcellular Fractionation
Rats were killed by cervical dislocation and the livers 
rapidly excised and washed thoroughly in ice-cold 1.15% (w/v) KCl. The 
livers were blotted dry and weighed prior to scissor-chopping and 
homogenization (see above) in 5 volumes (w/v) of 20 mM Tris-HCl buffer 
(pH 7.4) containing 250 mM sucrose and 5.4 mM EDTA (SET buffer) .
All samples were kept at 0-4° during the subsequent processing procedures.
The liver homogenate was centrifuged at 600 gav (2,200 rev. min-1) for 
10 min in a 8 x 50 ml aluminium angle head rotor in a M.S.E. H.S.18 
centrifuge. The crude nuclear pellet so obtained was resuspended in 
half the original volume of SET buffer and recentrifuged at 600 gav for 
10 min. The washed nuclear pellet was resuspended in SET buffer and 
stored in ice. The post-nuclear supernatant was centrifuged at 5,800 gav
(6,500 rev. min-1) for 10 min, and the pellet so obtained resuspended 
in half the original volume of SET buffer and recentrifuged at 5,000 gav 
for 10 min. The washed mitochondrial pellet so obtained was suspended 
in SET buffer and saved. The post-mitochondrial supernatant was then 
centrifuged at 17,000 gav (12,000 rev. min-1) for 15 min. The crude 
lysosomal pellet was resuspended in SET buffer (half the original volume) 
and recentrifuged at 17,000 gav for 15 min. This pellet was suspended 
in SET buffer and stored in ice. The supernatant was centrifuged at
300,000 gav (65,000 rev. min-1) for 20 min in a M.S.E. S.S.65 centrifuge. 
The crude microsomal pellet deposited was suspended in SET buffer and 
recentrifuged at 300,000 gav for 20 min. The washed microsomes were then 
suspended in SET buffer and stored in ice. The volumes of the supernatant 
fraction (cytosol) and resuspended pellets were all recorded. Fig. 2.1 
summarizes this procedure.
2.3.3. Protein Assays
Protein was determined by a modified method of Lowry 'et al.
t
(1951) using bovine serum albumin standards.
Reagents 
1% (w/v) CuS0i|.5H20 
2% (w/v) sodium potassium tartarate 
0.05 M NaOH containing 2% (w/v) Na2C03 
Folin-Ciocalteau reagent, diluted ^/3 with H2O
Bovine serum albumin in 0.05 M NaOH (50,100,150,200,250 \ig ml-1)
Method
Homogenates were diluted to appropriate concentrations using 
0.05 M NaOH. Aliquots of 0.5 ml were used for the assay. The C^SOi*, 
sodium potassium tartarate and Na2C03 solutions were mixed in the ratio 
1:1:100 immediately prior to use. The mixed solution (5.0 ml) and 
diluted homogenate (0.5 ml) were mixed and allowed to stand for at least
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10 min. Diluted Folin-Ciocalteau reagent (0.5 ml) was added and the 
solutions mixed immediately using a Vortex mixer. After at least 30 min 
the absorption at 720 nm was determined using a Unicam S.P.500 
spectrophotometer. Blanks (0.05 M NaOH) and bovine serum albumin 
standards were run in parallel.
2.3.4. Marker Enzymes
Glucose-6-Phosphatase (E.C.3.1.3.9.)
This enzyme was used as a microsomal marker and assayed 
by the measurement of inorganic phosphorus liberated during the hydrolysis 
of glucose-6-phosphate.
Reagents
0.3 M 3,3-dimethylglutarate (pH 6.4) containing 12.5 mM EDTA 
0.05 M glucose-6-phosphate, disodium salt 
6% (w/v) trichloracetic acid
5% (w/v) perchloric acid, containing 0 .6% ammonium molybdate 
0 .2% (w/v) ascorbic acid
Method
Each reaction vessel contained a suitably diluted tissue 
sample (0.5 ml) and 3,3-dimethylglutarate buffer (pH 6.4) containing 
EDTA (0.4 ml) . After pre-incubation for 5 min at 37°, glucose-6-phosphate 
(0.1 ml) was added to initiate the reaction and the tubes incubated a 
further 20 min at 37°. The reaction was terminated by the addition of 
trichloracetic acid (1.5 ml) and the denatured protein precipitated by 
centrifugation at 2,000 rev. min-* for 10 min. Perchloric acid (3.0 ml) 
containing ammonium molybdate was added to the decanted supernatant, 
and after mixing ascorbic acid (1.0 ml) added. The tubes were allowed 
to stand at ambient temperature for 30 min before determining the 
absorption at 720 nm.
Standards (containing 0.1-1.0 yg atom phosphorus) and blanks 
were run in parallel with the tissue samples.
Succinate Dehydrogenase (E.C.1.3.99.1.)
: This enzyme was used as a mitochondrial marker, and was
determined by a modified method of Pennington (1961) using the dye 
electron acceptor 2- (p-iodophenyl)-3-(p-nitrophenyl)-5-phenyltetrazolium 
chloride (INT).
Reagents
0.2 M 'sodium phosphate buffer (pH 7.4) containing 1.25 mg ml-* INT 
0.3 M sodium succinate (pH 7.4)
0.3 M sodium malonate (pH 7.4)
96% (v/v) ethanol/ethylacetate/10% trichloracetic acid (13:20:2)
Method .
Phosphate buffer (0.25 ml) containing 1.25 mg ml-* INT 
was added to suitably diluted subcellular fractions (0.5 ml) . The tubes 
were pre-incubated for 5 min at 37°, prior to initiating the reaction 
with sodium succinate (0.25 ml) . A further 10 min incubation at 37° 
was allowed. Tissue blanks were treated similarly, but sodium malonate 
(0.25 ml) , an inhibitor of succinate dehydrogenase, was substituted for 
the succinate1. The reactions were terminated by the addition of the 
ethanol/ethylacetate/trichloracetic acid reagent (6 ml) and mixing.
The solutions were centrifuged at 2,000 rev. min.”* for 10 min to remove 
any turbidity, and finally the supernatants were read at 490 nm using a 
Unicam S.P.5CO spectrophotometer. Actual concentrations of reduced INT 
were calculated from an extinction coefficient of 20 mM-*cm-*.
Acid Phosphatase (E.C.3.1.3.2.)
Total acid phosphatase was measured by the method of Neil 
and Horner (1964) using p-nitrophenyl phosphate as the substrate. The 
distribution of lysosomes was estimated from the activity of the acid 
phosphatase in each fraction.
Reagents 
0.01 M p-nitrophenyl phosphate 
0.1 M NaOH
0.2 M sodium acetate buffer (pH 5.0) containing 0.25% (w/v) Triton X-100 
Method
Suitable dilutions of tissue homogenates (0.2 ml) were 
pre-incubated to 37° for 5 min in the presence of acetate buffer (0.3 ml) 
containing 0.25% w/v Triton X-100. After this time the reaction was 
initiated by the addition of p-nitrophenyl phosphate (0.5 ml).
Suitable substrate blanks were incubated in parallel. The reaction was 
terminated after 15 min by the addition of the NaOH (5 ml) . The solutions 
were centrifuged at 2,000 rev. min-1 for 10 min to remove any turbidity 
and the yellow colour of the supernatant quantified at 400 nm in a 
Unicam S.P.500 spectrophotometer. Values for the amount of p-nitrophenol 
produced were calculated using an extinction coefficient of 18.5 mM^cm”*.
2.4. Spectrophotometry
All spectral measurements of microsomes were made using either 
a Perkin-Elmer 356 dual beam dual wavelength spectrophotometer or an 
Aminco DW2 UV-Vis spectrophotometer. Both instruments had facilities 
for temperature control of the cuvettes, hence unless otherwise stated 
all measurements were made at 37°. Both instruments could be used in 
either the split beam mode (using two cuvettes, Xi=X2) or in the dual 
beam collimated mode (only one cuvette utilized, Xi^X2)• The dual beam 
dual wavelength mode is advantageous for kinetic studies since both 
beams pass through a single cuvette, therefore unequalities in the turbidity 
of samples may be automatically corrected.
2.4.1. Cytochrome P-450 Measurements
Cytochrome P-450 was determined by the method of Omura and 
Sato (1964) assuming an extinction coefficient of 91 mM-1cm-1.
2.4.2. Substrate-induced Binding Spectra
These were determined by a modified method of Schenkman et al. 
(1967). Microsomes (6 ml) diluted to 1 mg ml”* in 66 mM Tris-HCl buffer 
(pH 7.4) were divided equally between two cuvettes. The cuvettes were 
sealed with Sub^^ seal (Gallenkamp & Co. Limited) silicone rubber self­
sealing stoppers and placed in the primary cell compartment of the spectro­
photometer. A baseline of equal light absorbance between 350 and 500 nm was 
constructed and recorded. Substrate, in yl quantities of a solution in 
water or dimethylformamide (Koch-Light Laboratories Limited) was injected 
through the stopper of the sample cuvette using a Terumo^ (Shandon Scientific 
Co. Limited) microlitre syringe. The microsomal suspension was mixed by 
gentle inversion. Similarly an equal volume of solvent was added to the 
reference cuvette. The difference spectrum between 350 and 500 nni was 
recorded. To obtain Ks values (Schenkman et al., 1967) successive aliquots 
of substrate solution were added and the spectra at each.concentration 
recorded. The kinetic parameters (apparent Ks and apparent Araax values) 
were Obtained from a double reciprocal plot (Schenkman et al., 1967) , as 
shown in Fig. 2.2.
2.5. Cautionary Notes Regarding Kinetic Parameters
and Spectral Measurements
It should be realized that the kinetic parameters obtained 
using microsomal suspensions are not absolute, but only relative. Since 
many substrates of the mixed function oxygenase system are insoluble 
in water the concentration quoted is not necessarily that which is in 
solution. Hence 1 mM cyclohexane for example merely means that each 3.0 ml 
of microsomal suspension contains 3 ymols cyclohexane, whether in suspension 
or in solution. However the activity of the mixed function oxygenase
FIGURE 2.2.
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system cannot be interpreted as being dependent purely on the aqueous 
solubility of substrate. A complex equilibrium seems to be involved 
between undissolved substrate, aqueous substrate and substrate dissolved 
in the lipid membranes of the microsomes. This indicates that kinetics 
of drug binding and metabolism in microsomal fractions must be interpreted 
with extreme caution.
Although dimethylformamide can show- a weak type RI binding 
spectrum with rat hepatic microsomes, none could be detected with volumes 
of less than 2 yl ml”* (25 mM) . Frequently (depending on substrate utilized) 
at least twice this concentration of dimethylformamide may be used without 
ill effects upon the microsomal parameters measured. Dimethylformamide 
at the concentrations stated above does not alter the oxygen or NADPH 
utilization (Wolf, et al., 1975), or effect the metabolism of biphenyl 
(Elcombe and McPherson, unpublished results) or p-nitroanisole (Elcombe, 
unpublished observations) in rat hepatic microsomes.
In the present study we routinely took 5 yl dimethylformamide 
per 3 ml microsomal suspension to be the maximum allowable concentration. 
Hence, where dimethylformamide was used, stock solutions of substrates 
at concentrations of 125, 250 and 500 mM were employed.
2.6. NADPH; Regeneration and Degradation
In experiments lasting longer than 2-3 min a NADPH- 
regenerating system was employed. This consisted of 3.3 mM glucose-6- 
phosphate and 2 units ml-* of glucose-6-phosphate dehydrogenase (E.C.1.1.1.49) 
Under metabolizing conditions in the presence of 100-400 yM NADPH, this 
system sufficed to keep a stable reduced cofactor concentration.
For certain studies in which NADPH rather than a regenerating 
system was used, it was necessary to oxidize the NADPH rapidly and 
efficiently. This was achieved by the addition of 20 units ml“* 
glutamate dehydrogenase (E.C.1.4.1.3.), 2.5 mM sodium a-oxoglutarate
and 5.0 mM NH^Cl to the microsomal suspension. This system was shown to 
completely oxidize 300 yM NADPH within one minute.'
2.7. Covalent Binding Studies
The apparently irreversible binding (covalent binding) of 
ll+C-isosafrole related material was determined in the subcellular 
fractions (nuclear, mitochondrial, lysosomal, microsomal and cytosol) 
obtained from the livers of rats pretreated with ***C-isosafrole. ^C- 
isosafrole was diluted with non-radioactive isosafrole to a specific 
activity of 1 mCi mmol”*. This was administered to the rat i.p. at a 
dose level of 150 mg kg~* once daily for 4 days. The rat was killed and 
the liver processed as described earlier.
The covalent binding of ltfC-isosafrole related material 
was also investigated i.n V'Ctro utilizing isolated hepatocytes and 
microsomal suspensions.
Isolated hepatocytes obtained from 60-80 g male rats were 
prepared by the method of Fry et al., (1975). The hepatocytes (about 
2 x 106 cells per ml), suspended in a minimal essential medium (see 
reagents section), were incubated in 5 ml volumes with 175 yM 11+C-iso- 
safrole (0.874 yCi ml”*) for 25 min at 37°.
The cells were then sedimented by centrifugation (200 gav 
x 2 min) and washed with 1.15% (w/v) KCl, and re-sedimented. The cell 
pellet was homogenized in 20 mM Tris-HCl buffer (pH 7.4) containing 
250 mM sucrose and 5.4 mM EDTA, and subcellular fractions prepared as 
described previously.
The irreversible binding of llfC-isosafrole related material 
to hepatic microsomes obtained from rats after different pretreatments 
was also investigated. Pretreatment schedules are described earlier.
2.7.1. Extraction of Homogenates
Non-covalently bound lltC-isosafrole related material was 
extracted from tissue homogenates using a sequential extraction procedure.
Various subcellular fractions (5 ml) suspended in 20 mM 
Tris-HCl buffer (pH 7.4) containing 250 mM sucrose and 5.4 mM EDTA were 
added to absolute ethanol (10 ml). The denatured protein formed was 
precipitated by centrifugation (2,000 rev min”* x 10 min) in a bench 
centrifuge. The ethanolic supernatants were decanted and saved. Further 
supernatants were also collected.
The protein pellets were extracted sequentially with 5 ml 
aliquots of the following reagents: 70% (v/v) ethanol, 0.25 M Tris-HCl 
buffer (pH 7.4) twice, 70% (v/v) ethanol, 96% (v/v) boiling ethanol twice, 
acetone:chloroform (4:1) twice, and 70% (v/v) ethanol. The protein 
pellets obtained were finally stored under distilled water (5 ml).
All extractions were facilitated using a 'tumble type' 
mixer for 10 min, and centrifugation was effected with a bench 
centrifuge (2,000 rev. min“* x 10 min).
2.8. , Solubilization of Protein and Scintillation.Counting
2.8.1. Preparation of Samples
Reagents
SHT solubilizer
NaOH 80 g
H20 600 ml
methanol 300 ml
triton X-405 100 ml
tT21 scintillant
toluene 1240 ml
triton X-100 800 ml
toluene SMI concentrate 360 ml
SMI concentrate consists of toluene (2,400 ml) and 
Scintimix SMI (100 g) . Scintimix SMI (Koch-Light Limited) is 
composed of 91% PPO (2,5-diphenyloxazole) and 9% bis MSB (l,4-di(2- 
inethylstyryl)benzene) .
Method
Tissues were removed from the animal, weighed and homogenized 
in water to give a 10% (w/v) homogenate. Solubilization was carried out 
by the method of Dent and Johnson (1974). Duplicate samples of tissue 
homogenate (0.5 ml) were added to SHT solubilizer (0.5 ml) in scintillation 
vials; the vials were then capped and heated to 50° for 1 hour in a 
sonicating bath and finally allowed to cool. 4.4 M HNO3 (0.25 ml) was 
added to neutralize the SHT, then scintillant (10 ml of tT21) was 
added with thorough shaking.
Subcellular fractions required no solubilization, hence 
duplicate samples (50 yl) were diluted to 1.0 ml with water and added 
directly to tT21 scintillant (10 ml).
Protein pellets obtained from extraction of various subcellular 
fractions during the covalent binding studies were solubilized and 
prepared for scintillation counting as described above. It was 
unnecessary to solubilize the supernatants obtained from the covalent 
binding studies. Hence these samples (1 ml) were added directly to tT21 
scintillant (10 ml).
2.8.2. Scintillation Counting
All samples were counted for 4 min with a 2% error, using 
either a Nuclear Chicago Mk II or an Intertechnique SL40 4K scintillation 
counter. Standardization was by an external standard channels ratio 
method. Counting efficiencies were calculated by computer; the pre-existing 
quench curve being verified for selected samples using ^C-hexadecane as a 
standard. '■
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3.1. INTRODUCTION
■ , . Franklin (1971) and Philpot and Hodgson (1972) independently
reported that methylenedioxyphenyl (MDP) compounds react with microsomal 
suspensions in the presence of NADPH to produce characteristic difference 
spectra. Generally two Soret peaks were observed, a large maximum at 
about 455 nm and another at about 430 nm. Some disagreement is apparent 
between these workers, since Franklin (1971) found that the presence of 
oxygen was obligatory while Philpot and Hodgson (1972) decided that oxygen 
was not a prerequisite for the formation of this unusual spectrum and was 
in fact inhibitory. Parke and Rahman (1971) observed this abnormal spectrum 
while examining hepatic microsomes obtained from rats pretreated with a MDP 
compound (safrole) and postulated the induction of a novel haemoprotein.
Because of the findings by Parke and Rahman (1971) and the 
discrepancies between the work of Franklin (1971) and Philpot and Hodgson 
(1972), I undertook to investigate the interactions of MDP compounds with 
hepatic microsomes from a mechanistic viewpoint.
3.2. METHODS
Oxidized Type I and Type RI binding spectra were determined 
as described earlier, using a microsomal protein concentration of 1 mg ml-1 
at 37°. Phenobarbitone-induced microsomes were used throughout, since 
larger absorption maxima were obtained when compared with control microsomes 
(i.e. microsomes from untreated rats). Preliminary experiments indicated 
that no qualitative differences existed between phenobarbitone-induced and 
control microsomes.
The formation of the 427 and 455 nm absorption maxima was 
studied using either the split beam mode (A^  = A2) or t i^e dual beam wave­
length (\i = 455 nm; A 2 = 490 nm) mode.
Unless otherwise stated the sensitivity range employed was 
0.01A or 0.005A full scale deflection, the slit width was 4.0 nm and the 
scanning speed 2 nm sec”*. When the Aminco DW2 spectrophotometer was used
rapid repetitive scanning was possible at speeds of 10 or 20 nm sec”1. 
Specific methodology is described in the legends of the relevant Figures.
3.3. RESULTS
3.3.1. Oxidized Binding Spectra of MDP Compounds and Analogues
with Phenobarbitone-induced Hepatic Microsomes
The MDP compounds used in this study elicited Type I or Type
RI binding spectra with phenobarbitone-induced rat hepatic microsomes. The
binding spectra of methylenedioxybenzene (Type I) and piperonyl alcohol
(Type RI) are illustrated in Figs. 3.1. and 3.2. Results obtained for other
MDP compounds and their analogues are summarized in Table 3.1. Since
dimethylformamide was utilized as a solvent for the MDP compounds, it was
also used as a control in the absence of MDP compounds. The addition oif
dimethylformamide to microsomes resulted in an extremely weak Type RI
binding spectrum. The maximum amount of dimethylformamide employed in
these studies was 25 mM, and at this concentration no binding spectrum
was apparent. Indan was included in these studies because of the similar
"size" of the molecule to the methylenedioxybenzene ring. Allylbenzene
and allyl alcohol were used in order to assess the contribution of the allyl
grouping present in safrole to the spectra. Most of the compounds employed
elicited the formation of Type I spectra; however, as will be seen from
Table 3.1., Type RI spectra were observed with some of the more hydrophylic
compounds such as sulphoxide and piperonyl alcohol.
K values, calculated by the method of Schenkman et al., (1967) s -----
were in the order of 4-40 yM for the Type I compounds studied. A typical Kg 
plot for safrole with phenobarbitone-induced microsomes is shown in Fig. 3.3.
FIGURE 3.1. ■
The Type I Binding Spectrum of Methylenedioxybenzene 
with Phenobarbitone-induced Rat Hepatic Microsomes
001 A
490450370 410
Phenobarbitone-induced microsomes were suspended to a 
final protein concentration of 1 mg ml-1 in 66 mM Tris- 
HC1 buffer (pH 7.4). The microsomes were divided between 
two cuvettes and a baseline of equal light absorbance 
between 350 and 500 nm recorded (—) . Methylenedioxy­
benzene (835 yM) was added to the sample cuvette and the 
spectrum recorded (— ©  —  © —).
FIGURE 3.2.
The Type RI Binding Specgrum of Piperonyl Alcohol with 
Phenobarbitone-induced Rat Hepatic Microsomes
0005A
370 410 450 490
Conditions were as described in Fig. 3.1. except that 
piperonyl alcohol (833 yM) was added to the microsomal 
suspension.
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FIGURE 3.3.
Ks Plot for Safrole with Phenobarbitone-induced Microsomes
30
20 -
10 -
0*100-050
Safrole Cone CpM)
Phenobarbitone-induced microsomes at a protein concentration 
of 1 mg ml-1 were used. Safrole as a 250 yM solution in 
dimethylformamide was added to the microsomal suspension in 
yl quantities to give a final safrole concentration of 8- 
800 yM. The difference spectra were recorded and the AApg^. 
trough values used to construct the double reciprocal plot.
'3.3.2. Formation of the 427/455 nm Spectrum
In agreement with the work of Franklin (1971) and Philpot 
and Hodgson (1972), I found that the addition of NADPH to an aerobic 
suspension of phenobarbitone-induced or control microsomes containing 
certain MDP compounds resulted in a dramatic modification or disappearance 
of the oxidized binding spectrum of the MDP compounds followed by a time 
dependent formation of absorption maxima at 427 and 455 nm (Fig. 3.4.).
The absorbance at 427 nm was not due to interference by reduced cytochrome 
bs since NADPH was present in both cuvettes.
Although Na2S20if could not mediate the production of this 
unusual spectrum, its addition after NADPH "froze" the absorption spectrum. 
NADPH was specific for the formation of the 427/455 nm spectrum; NADH (500 yM) 
could not act as a substitute. This observation is contrary to the results of 
Philpot and Hodgson (1971-1972) with piperonyl butoxide, where NADH was 
reported to be able to support the partial formation of the 427/455 nm 
spectrum. In the present study the use of an oxygen electrode technique 
(Wolf et al., 1975) demonstrated that the formation of the 427/455 nm 
absorption spectrum was paralleled by an increase in oxygen consumption of the 
microsomes (Fig. 3.5.).
These results indicate also that oxygen is required for the 
production of this characteristic spectrum. Furthermore when the 
microsomes were deoxygenated by gassing with nitrogen and the addition of 
10 mM glucose and 4 units ml”1 glucose oxidase (E.C.1.1.3.4.) (Staudt 
Lichtenberger and Ullrich#) 1974, the 427/455 nm absorption spectrum could not 
subsequently be obtained on the addition of safrole and NADPH. Hence, in 
agreement with Franklin (1971) , the present work has established the absolute 
requirement both of NADPH and of oxygen for the formation of the 427/455 nm 
absorption spectrum from MDP compounds. This finding indicates that 
metabolism of the MDP compound is necessary prior to the appearance 
of the 427/455 nm-spectrum.
FIGURE 3.4.
Formation of the 427/455 nm Spectrum from Safrole, NADPH
and Aerobic Phenobarbitone-induced Microsomes
0-005 A
Phenobarbitone-induced microsomes (1 mg ml~*) were divided 
between .two cuvettes and a baseline of equal light 
absorbance obtained between 400 and 500 nm (— ) . Safrole 
(417 yM) was added to the sample cuvette and the spectrum 
recorded (- ©  - ©  -) . NADPH (400 yM) was added to both 
cuvettes and the spectrum repetitively scanned every 30 
seconds. Representative scans are numbered.
FIGURE 3.5.
Safrole-induced Oxygen Consumption in Hepatic Microsomes
NADPH
safrole
25nmol 0„
Tlme(min)
Phenobarbitone-induced microsomes were suspended to a 
final protein concentration of 1 mg ml-1 in 66 mM Tris- 
HCl buffer (pH 7.4) containing a NADPH generating system 
(Chapter 2). NADPH (400 yM) was added at zero time and 
the endogenous oxygen consumption recorded. Safrole 
(208 yM) was added after a few minutes and the increased 
oxygen consumption measured.
3.3.3. The Effect of Modifiers of Monooxygenation on the
Formation of the 455 nm Absorption Maximum
In the present study the effects of inhibitors on the rate 
of formation of the 455 nm absorption maximum were investigated. Classical 
enzyme inhibitors (e.g. 27-ethylmaleimide, iodoacetic acid and iodoacetamide) 
specific inhibitors of cytochrome P-450 (e.g. metyrapone and SKF-525A) and 
alternative substrates (e.g. biphenyl and aniline) were employed.
The rate of appearance of the 455 nm maximum was measured 
using a spectrophotometer in the dual beam dual wavelength mode. That 
is, only one cuvette was used, both the sample light beam (Xj = 455 nm) 
and the reference light beam (X2 = 490 nm, an isosbestic point) passed 
through the same cuvette.
As illustrated in Fig. 3.6. the rate of formation of the 
455 nm absorbance was measured in the absence and presence of the modifier 
(in this instance iV-ethylmaleimide). It is clearly seen that the rate 
of formation was decreased by more than 50% in the presence of 77-ethylmale- 
imide. Figure 3.7. summarizes the data obtained from similar experiments 
utilizing other modifiers. The classical enzyme inhibitors (iodacetamide, 
iodoacetic acid and il/-ethylmaleimide) and the specific cytochrome P-450 
inhibitors retarded the rate of increase of the 455 nm maximum by 50% 
or more. Furthermore the presence of alternative substrates of the 
system (e.g. biphenyl, butylated hydroxytoluene, aniline), also led to 
inhibition of between 30 and 80% of the control values.
Of .interest at this point is the observation that 
dithiothreitol, a free radical scavenger, had no effect on the rate of 
appearance of the 455 nm absorbance maximum. This will be discussed later.
Addition of NADH (417 yM) was found to increase the rate of 
formation of the 455 nm absorption maximum above the control value by about 
30%. This phenomenom was not observed if the NADH was replaced by an ’extra 
417 yM NADPH. t Hence the concentration of NADPH used was not rate limiting.
FIGURE 3.6.
The Effect of ^-ethylmaleimide on the Rate of Formation 
of the 455 nm Absorption Maximum
0-003 A
NEM
Time (min)
Phenobarbitone-induced microsomes (1 mg ml”1) in 66 mM 
Tris-HCl buffer (pH 7.4) containing 3.3 mM glucose-6- 
phosphate, 2 units ml”1 glucose-6-phosphate dehydrogenas* 
and 167 yM safrole were allowed to equilibrate to 37° in 
the spectrophotometer. NADPH (200 yM) was added and 
AAi+55-490 recorded with time. The experiment was 
repeated in the presence of 2 mM ^-ethylmaleimide (NEM).
FIGURE 3.7.
The Effect of various Modifiers of Monooxygenation 
on the Formation of the 455 nm Absorbance
Concentrations of modifiers: biphenyl, hexobarbitone
aniline and butylated hydroxytoluene, 1.67 mM; dithio 
threitol, /'/-ethylmaleimide, 2.34 mM; iodoacetamiae, 
iodoacetic acid, 4.7 'mM; SKF-525A, 83■yM; metyrapone, 
66.7 yM; NADH, 417 yM; 'Extra NADPH1, 417 yM.
Experimental conditions v;ere as defined in Fig. 3.6. 
Inhibition of the rate of formation of the 455 nm 
absorbance is indicated as.a percentage of control 
values (in absence of modifier). All values are 
mean ± SD (n=4).
From this it is apparent that the synergistic effect of NADH previously 
reported for the monooxygenation of many compounds (Cohen and Estabrook, 
1971a,b,c; Correia and Mannering, 1973a,b; Netter and Illing, 1974) 
extends to the formation of the 455 nm absorption maximum.
Since an absolute requirement for NADPH and oxygen has 
been demonstrated both in this work and in previous studies (Franklin, 
1971) and since inhibitors and other substrates of cytochrome P-450 
retard the formation of the 455 nm absorption peak, it appears that 
oxidative metabolism of MDP compounds via cytochrome P-450 is a 
prerequisite for the generation of the unusual difference spectrum. 
Additional evidence is derived from the observation that NADH synergizes 
but does not mediate (in the absence of NADPH) the formation of the 
455 nm absorption maximum.
It thus seems likely that the 427/455 nm complex is 
the optical manifestation of a MDP metabolite-reduced cytochrome P-450 
complex.
3.3.4. Stability of the 455 nm Absorbing Complex
After generation of the 427/455 nm absorption spectrum from 
safrole, oxygen and NADPH in phenobarbitone-induced microsomes the 
microsomal suspension (20 ml) was dialysed against 800 ml 66 mM Tris- 
HC1 buffer (pH 7.4) for 6 hours at 4°. The microsomal suspension (5 ml) 
was divided between two cuvettes, Na2S20it was added to the sample cuvette 
and the difference spectrum recorded. Less than a 10% loss of the 455 nm 
absorption maximum was observed. This indicates the high stability of 
the proposed MDP metabolite-reduced cytochrome P-450 complex.
3.3.5. The Effect of the Formation of the 427/455 nm Absorbing
Complex on the Binding of Carbon Monoxide and Type II
Compounds to Oxidized Cytochrome P-450
The 427/455 nm absorbing complex was produced in the normal 
manner by incubating phenobarbitone-induced microsomes with safrole, NADPH
and oxygen. The microsomal suspension was then dialysed for 6 hours as 
described above, and the apparent concentration of■ cytochrome P-450 was 
determined by the method of Omura and Sato (1964a). It was observed 
that the magnitude of the 450 nm peak was drastically diminished when 
compared with microsomal suspensions which had been pre-incubated with safrole 
(but not NADPH) and then dialysed as described above. The magnitude of 
the apparent decrease in the carbon monoxide difference spectrum was 
dependent on the original size of the 455 nm absorption maximum. That is, 
the larger was the 455 nm absorption peak the smaller was the carbon 
monoxide difference spectrum. Similarly it was observed that, after 
formation of the 427/455 nm absorbing complex* aniline and imidazole (Type 
II compounds) would not elicit a binding spectrum with the oxidized microsomes 
after dialysis.
Hence it seems most probable that the 427/455 nm spectrum is 
due to the binding of a MDP metabolite to the haem of reduced cytochrome 
P-450.
3.3.6. The MDP Metabolite-Oxidized Cytochrome P-450 Complex
After the formation of the 427/455 nm absorbing complex from 
safrole, NADPH and phenobarbitone-induced microsomes, the reducing conditions 
were removed (either by the addition of glutamate dehydrogenase, a-oxo- 
glutarate and NH^Cl; or by merely allowing the NADPH to become exhausted) , the 
427 and 455 nm absorption bands disappeared with the simultaneous appearance 
of a single absorption maximum at 438 nm (Fig;1 3.8.). This absorption peak 
decayed slowly with time in the presence of excess substrate (i.e. safrole) 
(Fig. 3.9.).
The addition of a chemical reducing agent (Na2S204, NADH or 
NADPH) to microsomes exhibiting the 438 nm absorption maximum resulted 
in the reappearance of absorption maxima and 427 end 455 nm. Furthermore 
the amplitude of these maxima were dependent on the magnitude of the residual
438 nm absorption peak.
FIGURE 3.8.
Observation of the Oxidized Safrole Metabolite-Cytochrome P-450
Complex after Removal of Reducing Conditions
0-005 E
470 490450430 nm
The 427/455 nm spectrum was generated as described in Fig. 3.4. 
Safrole (208 yM) binding spectrum (- O  “ O  “) • Ihe formation 
of the 427/455 nm spectrum was observed by repetitive scanning 
at 30 second intervals (scans are numbered in sequence). After 
the 427/455 nm spectrum reached a maximum, glutamate dehydrogenase, 
a-oxoglutarate and NH^Cl were added to both cuvettes to remove 
NADPH, as described in Chapter 2 (METHODS). The oxidized spectrum 
was then recorded (- ®  - @  -) .
FIGURE 3.9.
The Stability of the 438 nm Spectrum
0005 E
390 410 30 450370 470 490nm
The 438 nm spectrum was generated as described in 
Fig. 3.7., and continuously monitored by repetitive 
scanning every 30 seconds. The arrow indicates the 
decrease in absorbance at 438 nm with time.
Hence it appears that these two spectra are due to identical 
complexes, of a MDP metabolite with cytochrome P-450, which differ merely 
in their redox state. The 427/455 nm spectrum represents the reduced (Fez ) 
complex and the 438 nm spectrum represents the oxidized (Fe3+) complex.
3.3.7. Observation of the 427/455 nm and 438 nm Absorbing Complexes
with Various MDP Compounds and Analogues
In the present study a number of compounds have been examined 
in an attempt to understand the criteria for the formation of the reduced 
MDP metabolite-cytochrome P-450 complex (as observed by the formation of a 
427/455 nm absorptive spectrum) and the corresponding oxidized 438 nm 
absorbing complex. The results of this study are shown in Table 3.2. For 
convenience all compounds were at a final concentration of 417 yM. It is 
noteworthy that piperonyl butoxide, at this concentration, was a very poor 
example of compounds able to exhibit this phenomenon. To produce a 
reasonably sized 427/455 nm spectrum from piperonyl butoxide such as those 
demonstrated by Franklin (1971; 1972a) and Philpot and Hodgson (1972) mM 
concentrations were required. The use of such large quantities resulted in 
insolubility problems and resultant turbidity, which caused inaccurate 
spectrophotometric results due to extremely high levels of light scattering 
and turbidity enhancement of spectral absorption bands.
Table 3.2. indicates that in general whenever a 427/455 nm 
spectrum was observed the removal of reducing conditions led to the formation 
of the oxidized 438 nm absorption maximum.
A representative collection of 427/455 nm spectra are shown in 
Fig. 3.10 (a-d) . These examples include both Type I and Type RI compounds and 
it is clearly seen that the relative magnitudes of the 427 and 455 nm 
absorption peaks varied, depending upon the MDP compound employed. With 
piperonyl alcohol and methylenedioxybenzene the 427 nm peak was much larger 
than the 455 nm absorption maximum; however with piperonyl butoxide the 
427 nm absorbance was observed merely as a shoulder on the 455 nm peak.
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FIGURE 3.10(a)
Formation of the 427/455 nm Spectrum
using Piperonyl Alcohol
0005 A
470420
nm
370
Conditions as in Fig. 3.4., except the
substrate was piperonyl alcohol (417 yM)
FIGURE 3.10 (B)
Formation of the 427/455 nm Spectrum
using Piperonyl Butoxide
0 0 0 5  A
nm
Conditions as in Fig. 3.4., except the
substrate was piperonyl butoxide (417 yM)
FIGURE 3.10(c)
Formation of the 427/455 nm Spectrum
using Sesamex
Conditions as in Fig. 3.4., except the 
substrate was sesamex (417 yM).
FIGURE 3,10(d)
Formation of the 427/455 nm Spectrum using Sulphoxide
0005 a;
470A2i
Conditions as in Fig. 3.4., except the
substrate was sulphoxide (417 yM) .
The reasons for these differences are not immediately apparent. One 
possibility is that the variation in the 427/455 ratio is because a 
standard substrate concentration (417 yM) was used, and not a concentration 
corresponding to the or Ks value for each compound. This hypothesis is 
supported by results which I have obtained with safrole. At very low 
safrole concentrations (20 yM) only a 427 nm absorption maximum was 
observed (Fig. 3.11.); on increasing the safrole concentration the 427/455 
ratio decreased (Fig. 3.12.).
The explanation for this change in peak ratio with increasing 
substrate concentration is not obvious. The logical explanation is an optical 
cancelling effect, since the peak at 427 nm is very near the trough of the 
Type I binding spectrum at 422 nm. Hence a mutual cancelling of peak and 
trough could occur. However the decrease in the 427/455 peak ratio with 
increasing safrole concentration was still observed even after addition of 
Na2S20y, which abolishes the Type I binding spectrum (Schenkman et al., 1967).
It is also possible that two distinct metabolites of safrole
are produced, each having a different value and that the metabolite which
binds to cytochrome P-450 resulting in the appearance of the 427 nm peak has
the lower K , hence as the concentration of substrate is increased the 427 nm m
peak will attain a maximum while the 455 nm peak will still be increasing.
A third hypothesis is that the 427 and 455 nm peaks are due to 
the same metabolite of safrole binding to different sites or even to different 
cytochrome(s) P-450.
No evidence is available directly to validate these possibilities 
however the problem will be clarified to some extent in a later section of this 
thesis.
As can be seen from Table 3.2., the methylene bridge of the 
1,3-dioxolane ring appears to be essential for the production of the MDP 
metabolite-cytochrome P-450 complex. Franklin (1971) suggested that there 
are two major requirements for the formation of the 427/455 nm spectrum from
FIGURE 3.li.
The Lack of 455 nm Absorbance 
at Low Safrole Concentrations
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Conditions were as in Fig. 3.4./ except
the safrole concentration was 20 yM.
FIGURE 3.12.
The Dependence of the 427/455 Ratio
on Safrole Concentration
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The 427/455 nm spectrum was generated as described 
in Fig. 3.4., using safrole concentrations of 8- 
208 yM. Two different preparations of phenobarbitone- 
induced microsomes were used (Qand@).
MDP compounds. First the MDP compound must be lipid soluble and secondly 
it must bind to oxidized cytochrome P-450 in the Type I mode. My 
observations tend to support the first suggestion to some extent. However 
piperonyl alcohol resulted in a better 427/455 nm spectrum than piperonyl 
butoxide (Table 3.2.) while the log P values for these compounds are 1.05 
and 5.2 respectively (Table 3.2.). In general, however, a certain degree 
of lipid solubility seems to be required. The present study has shown that 
Type RI compounds are also capable of being metabolized resulting in the 
generation of the 427/455 nm absorbing MDP metabolite-cytochrome P-450 
complex. For example, this type of spectrum was produced with the Type RI 
compounds piperonyl alcohol and sulphoxide. The latter compound reacted 
particularly well, almost to the same extent as the Type I compound safrole.
Although incapable of supporting the formation of the 
427/455 nm absorbing complex, Na2S20it was found frequently to enhance the 
absorption maxima. For example, with sesamol (Fig. 3.13.), no 427 or 455 nm 
absorption maxima were apparent after the addition of NADPH, but the 
subsequent addition of Na2S20i* resulted in a sizeable absorption maximum 
at 455 nm and a distinct shoulder at 427 nm.
It is possible that the metabolite, or metabolic intermediate, 
of sesamol is unstable in the presence of oxygen. Therefore under 
metabolizing conditions (i.e. aerobic) the metabolite may have only a 
transient existence, but on the addition of excess ^ 2520  ^the microsomal 
suspension becomes anaerobic and the metabolite of sesamol will be 
stabilized for long enough to become bound to cytochrome P-450.
3.4. DISCUSSION
The question as to the nature of the MDP metabolite or 
intermediate warrants further discussion. The results indicated in Table 3.2. 
indicate the importance of the methylene bridge. Demethylenation of MDP
compounds to the corresponding catechols and formate has been demonstrated
FIGURE 3.13.
Formation of the 427/455 nm Spectrum using Sesamol
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Conditions were as in Fig. 3.4., except the substrate 
was sesamol (833 yM). After incubation for 15 min 
with NADPH, Na2S20it (2-3 mg) was added to both 
cuvettes and the spectrum recorded (- A  - A  -) .
in microsomal systems (Casida et al., 1966; Kamienski and Casida, 1970). 
However the present study showed that catechol (the demethylenation product 
of methylenedioxybenzene) was incapable of eliciting a 427/455 nm spectrum 
(Table 3.2.). It is more likely that a more reactive intermediate of MDP 
compound metabolism is responsible for the formation of the characteristic 
spectrum. Once formed the MDP metabolite which forms a complex with 
cytochrome P-450 is a potent inhibitor of monooxygenation (Franklin, 1972), 
presumably due to inhibition of oxygen activation. Hence the observed insect­
icide synergist activity of MDP compounds (Hodgson and Philpot, 1974) is 
probably due to the binding of a metabolite .to the haem of cytochrome P-450 
hence inhibiting monooxygenation of the insecticide.
The nature of the active metabolite of MDP compounds has been 
the subject of much controversy. Hennessey (1965) has proposed that the loss 
of a hydride ion from the methylene bridge could load to the formation of an 
electrophilic benzodioxolium ion:-
This ion could react with a nucleophilic centre of a protein or might form 
a pi-bonded complex with iron.
Hansch (1968), on the basis of structure-synergistic activity 
relationships using substituent constants and regression analysis, has 
suggested that the methylene bridge of the 1,3-dioxolane ring may undergo 
homolytic cleavage resulting in the loss of a hydrogen atom:-
Thus the free radical so generated may be the active intermediate responsible 
for synergistic activity.
A third proposal is based on data using fluorene (Ullrich 
and Schnabel, 1973a). These authors demonstrated that during the oxidative 
metabolism of fluorene, absorption maxima at 374 and 446 nm are observed.
The 374 nm peak was also observed in a model system which was conducive to 
the formation of the fluorenyl carbanion, (Fig. 3.14.) Furthermore it was 
found that the 446 nm absorption band was enhanced under anaerobic conditions 
and discharged in the presence of carbon dioxide or oxygen with the formation 
of fluorene-9-carboxylic acid or fluorene-9-hydroperoxide respectively (Fig. 
3.14.). The authors concluded that the oxenoid species (Ullrich, 1972) which 
is active during monooxygenation reactions abstracts a proton from the 
methylene bridge at the 9-position of fluorene. The carbanion thus obtained 
reacts with the reduced cytochrome P-450 resulting in the formation of a peak 
at 446 nm. Ullrich and Schnabel (1973b), further suggested that this hypothesis 
could be extended to MDP compounds. However an examination of the chemistry of 
these compounds indicates that the methylene group of the 1,3-dioxolane ring 
is not acidic, hence the abstraction of a proton by the oxenoid species 
involved in monooxygenation is unlikely.
The halogenated hydrocarbons (Uehleke, Hellmer and Tabarelli, 1973) 
also elicit absorption maxima at 455 nm in the presence of NADPH (however 
only under anaerobic conditions) and recently it has been proposed that a 
carbene is produced during the metabolism of these compounds (Mansuy, 
Nastainczyk and Ullrich, 1974). Fig. 3.15a. indicates the proposed metabolism 
of halothane w a  cytochrome P-450, and the subsequent formation of a 
halothane metabolite cytochrome P-450 complex.
It is possible that a similar reaction occurs with MDP 
compounds, however hydrogen is not a good leaving group. Hence the 
formation of a carbene would not be via a direct 2H abstraction, but a 
hydroxylation of the methylene bridge may initially occur followed by an
Formation of the Fluorene Carbanion
(derived from Ullrich and Schnabel, 1973)
X ^ X - X N
X X X X
k x
H X:oo0
(1)
Fluorenyl \ carbanion
(X 374 nmj max
— —X X  X X  X x ,
00H
Fluorene-9-carboxylate Fluorene-9-hydroperoxide
2+Fe
Cytochrome P-450-
fluorenyl complex
(X 446 nm) max
(1) oxenoid species or potassium methylate, dimethyl sulphoxide and argon.
Possible Mechanisms of Carbene Formation
(a)
Halothane
(b) \
J: h2
"active
oxygen"
O'
singlet
carbene
'(c)
C:
> Fe2+ /
triplet
elimination reaction as indicated in Fig. 3.15b. The carbene produced 
could then bind to the haem of cytochrome P-450 (Fig. 3.15c.). In this 
methylene carbene complex with reduced cytochrome P-450, the carbene 
could be stabilized by the same type of iron-carbon o bond , with tt- 
back bonding as in the carbon monoxide or ethylisocyanide complexes of 
other ferroporphyrin proteins.
The present work has not identified which of these active 
intermediates is responsible for the formation of the 427/455 nm absorbing 
complex. However since the use of dithiothreitol, a free radical scavenger, 
did not inhibit the formation of the complex, it seems unlikely that a free 
radical mechanism is involved. Furthermore I have found that gassing of 
a microsomal suspension, exhibiting the 427/455 nm spectrum, with oxygen 
or carbon dioxide had no effect on the magnitude of the spectrum. Hence the 
presence of a carbanion is most unlikely since, as-shown by Ullrich and 
Schnabel (1973), the fluorenyl carbanion and the 446 nm spectrum (Fig. 3.14.) 
is discharged by oxygen and carbon dioxide resulting in the production of 
the hydroperoxide and carboxylic acid respectively. Other compounds have 
been shown to elicit 455 nm absorption maxima under metabolizing conditions. 
The best known examples are the amphetamines (Werringloer and Estabrook,
1973; Franklin, 1974a,b) and compounds related to SKF-525A (Buening and 
Franklin, 1974; Franklin, 1974c). However it should be emphasized that 
these compounds elicited only the 455 nm absorption peak, and not the 427 nm 
absorption maximum. This major difference shall be discussed in a later 
section of this thesis.
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4.1. INTRODUCTION
Kadlubar, Morton and Ziegler (1973) demonstrated that 
cytochrome P-450 can catalyse the organic hydroperoxide dependent 
(7-oxidation of several amines in the absence of NADPH and oxygen.
These authors suggested that the organic hydroperoxide may supply an 
alternate means of forming peroxy-haem, which may then function as an 
oxidant. Rahimtula and O'Brien (1974; 1975) have shown that cumene 
hydroperoxide may be substituted for NADPH and oxygen during cytochrome 
P-450 catalysed aromatic hydroxylation and O-dealkylation reactions.
These studies demonstrated that the rates oi; the cumene hydroperoxide 
mediated reactions were at least as high as those in which optimal 
amounts of NADPH were used instead. Furthermore, since carbon monoxide 
was incapable of inhibiting the cumene hydroperoxide reactions, the cytochrome 
P-450 did not pass through a Fe2+ state.
The present study was initiated to determine if cumene 
hydroperoxide could support the formation of MDP raetabolite-cytochrome 
P-450 complexes. Because the cytochrome does not become reduced, it 
was thought possible that the 438 nm absorbing complex (described in 
Chapter 3) could be observed directly upon the addition of a MDP compound 
and cumene hydroperoxide to hepatic microsomes.
4.2. METHODS
Phenobarbitone-induced rat hepatic microsomes were used 
throughout these experiments. Cumene hydroperoxide was employed as a 
9 mM stock solution in 66 mM Tris-HCl buffer (pH 7.4).
4.3. RESULTS
4.3.1. The Interaction between Cumene Hydroperoxide and
Phenobarbitone-induced Microsomes
The addition of 150 yM cumene hydroperoxide to rat hepatic 
microsomes resulted in the appearance of a transient absorption maximum 
at 442 nm. Concomitantly an absorption minimum at about 420 nm was 
observed (Fig. 4.1.).
The absorbance at 442 nm attained a maximum after approximately 
30 seconds and then rapidly decreased, however the trough at 422 nm 
remained. This absorption maximum at 442 nm has also been reported by 
Rahimtula et al., (1974) using rabbit microsomes. These workers have 
demonstrated the appearance of a novel EPR signal at about g = 2.0 which 
was associated with the addition of cumene hydroperoxide to the pheno­
barbitone-induced rabbit hepatic microsomes. By analogy to the reaction 
of H2O2 with metmyoglobin or cytochrome C peroxidase these authors have 
suggested that the novel EPR signal is due to presence of haem in the 
ferry 1 (Felf+) state. •
4.3.2. Cumene Hydroperoxide-mediated Formation of the MDP
Metabolite-Cytochrome P-450 Complex
The addition of cumene hydroperoxide to microsomes in the 
presence of certain MDP compounds resulted in the time dependent formation 
of an absorption maximum at 438 nm (Fig. 4.2.) . Both the rate of formation 
and the final magnitude of this absorption band was dependent on the 
original concentration of the MDP compound. It is noticeable that the 
oxidized binding spectrum (Type I or Type RI) of the MDP compound was 
abolished within 15 seconds after the addition of cumene hydroperoxide,
(Fig. 4.2.).
FIGURE 4.1.
The Addition of Cumene Hydroperoxide
to Phenobarbitone-induced Microsomes
0-01 A
370 400 3 0 490460
nm
Phenobarbitone-induced microsomes (1 mg ml"1) 
in 66 mM Tris-HCl buffer (pH 7.4) were divided 
between two cuvettes and a baseline of equal 
light absorbance obtained. Cumene hydro­
peroxide (150 yM) was added to the sample 
cuvette and the resultant spectra obtained at 
15 second intervals. 0“0 r 15 sec? Q - Q  , 30 
sec; A — A, 45 sec; A-A , 60 sec.
FIGURE 4.2.
Cumene Hydroperoxide-mediated Formation of the Safrole
Metabolite-cytochrome P-450 Complex.
I - The Oxidized Complex
O01 A
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Phenobarbitone-induced microsomes (1 mg ml-1) were divided 
between two cuvettes and a baseline of equal light 
absorbance obtained (— ). Safrole (250 yM) was added to 
the sample cuvette and the spectrum recorded ( ©-©). Cumene 
hydroperoxide (150 yM) was then added to both cuvettes and 
the spectrum scanned every 30 secs. (A/|l/©/$)*
The addition of a reducing agent (NADPH, NADH or Na2S20i4.) 
to a microsomal suspension exhibiting the 438 nm absorption peak resulted 
in the immediate appearance of absorption maxima at 427 and 455 nm, (Fig.
4.3.). The magnitudes of both the 427 and 455 nm peaks were directly 
proportional to the original magnitude of the 438 nm maximum. Figure
4.4. illustrates this relationship. The magnitude of the 438 nm absorption 
peak was in turn dependent on the safrole concentration used.
The concentration-dependent change in the 427/455 ratio, 
described in Chapter 3, was also observed after generation of the 438 nm 
spectral peak using cumene hydroperoxide and% safrole followed by chemical 
reduction with Na2S20it.
The ease with which the 438 nm and 427/455 nm spectra can be 
interconverted suggests that cumene hydroperoxide is capable of mediating 
the metabolism and subsequent formation of the MDP metabolite-cytochrome 
P-450 complex in a similar manner to NADPH and oxygen. In the former 
situation the spectrum of the MDP metabolite-oxidized cytochrome P-450 
complex may be observed directly, while in the presence of NADPH only the 
reduced complex is observed unless the microsomes are subsequently depleted 
of NADPH.
The apparent values (for the formation of the MDP metabolite- 
cytochrome P-450 complex) in the cumene hydroperoxide- and the NADPH- 
mediated reactions were determined by the measurement of the initial rates
of change in absorbance at 438 nm and 455 nm respectively. It was
found that the apparent values for both reactions were 18 yM (Fig.
4.5.); noticeably this value is almost identical to the Ks value for the 
Type I binding spectrum (18.5 yM) and the Ks (calculated from the
max455 or ^Amax438) values for the '438 nm complex" (16.7 yM) and the
"455 nm complex" (16.7 yM).
FIGURE 4.3.
Cumene Hydroperoxide-mediated Formation of the Safrole
Metabolite-cytochrome P-450 Complex.
II - The Reduced Complex
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Conditions as in Fig. 4.2. Safrole binding spectrum 
( 0 - 0 )t repetitive scans at 30 second intervals are 
numbered. Na2S204 (2-3 mg) was added to both cuvettes 
after 7 min and the spectrum recorded ( )  .
FIGURE 4.4.
The Relationship Between the 438 nm and 427/455 nm Spectra
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The 438 nm absorbance was obtained by incubating 
phenobarbitone-induced microsomes (1 mg ml-*) with 
cumene hydroperoxide (150 yM) and various safrole 
concentrations (10-833 yM). The microsomal 
suspensions were reduced with Na2S20  ^after the 
increase of absorbance at 438 nm had ceased. The 
maximum AAy3Q value was plotted against the AA427 
and AAy55 values (after reduction with Na2S20y) 
for various safrole concentrations.
FIGURE 4.5.
The Determination of Apparent values for the Formation 
of the 438 and 455 nm Absorption Maxima
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Phenobarbitone-induced microsomes (1 mg ml-1) were allowed 
to equilibrate to 37° in a spectrophotometer in the dual­
beam dual wavelength mode (Xj = 438 or 455 nm; X2 = 490 nm) . 
Safrole (8-833 yM) was added to the microsomes followed by 
cumene hydroperoxide (150 yM) or NADPH (200 yM) , the rate 
of increase of absorbance at 438 or 455 nm respectively was 
then recorded. A Lineweaver-Burk plot was constructed using 
the initial rate of change in absorbance.
In contrast with these results, Rahimtula and O'Brien 
(1975) found, using phenobarbitone-induced rabbit hepatic microsomes, 
that the values for aniline hydroxylation, 7-ethoxycoumarin deethylation 
and p-nitroanisole demethylation were profoundly different for the cumene 
hydroperoxide and NADPH reactions. For example, these workers showed 
that the Kju for p-nitroanisole demethylation was 39 pM with NADPH and 
4.0 mil with cumene hydroperoxide.
In the present work I have demonstrated the formation of 
the 438 nm absorption maximum and the subsequent appearance of the 427 and 
455 nm peaks on the addition of Na2S204 using several MDP compounds, 
including safrole, isosafrole, methylenedioxybenzene, sesamex and 
sulphoxide. A similar relationship was observed for these compounds 
such as that seen with safrole (Fig. 4.4.). Piperonyl butoxide, however, 
was incapable of forming the 438 nm absorption maximum at the concentrations 
employed (below 500 yM) , this is in agreement with results discussed in 
Chapter 3, using NADPH.
4.3.3. Stability and Properties of the 438 nm Absorbing Complex
The 438 nm absorbing complex, generated from safrole, 
cumene hydroperoxide and phenobarbitone-induced microsomes, was found 
to be stable for at least 2 hours at 37°. Furthermore the magnitude 
of the 438 nm absorption maximum was unchanged even after dialysis 
against 66 mM Tris-HCl buffer (pH 7.4) for 4 hours at 4° (microsomal 
suspension 10 ml; buffer 500 ml).
A microsomal suspension which had been incubated for 10 min 
with 150 yM cumene hydroperoxide and 200 yM safrole was dialysed as above 
to remove possible excess substrates and cumene hydroperoxide degradation 
products. The binding of carbon monoxide to the Na2S20  ^reduced dialysed 
microsomes was decreased by about 50%, when compared with dialysed 
microsomes which had been incubated in the presence of cumene hydroperoxide 
only. No Type I binding spectrum could be obtained on the addition of
cyclohexane or hexobarbital to dialysed microsomes which exhibited the 
438 nm spectrum. Similarly the Type II spectra of aniline and imidazole 
were barely detectable.
4.3.4. The Use of other Hydroxylating Agents
Hrycay et al. (1975) have demonstrated the hydroxylation of 
androstenedione by NalO^, NaC102, cumene hydroperoxide and H2O2 catalysed 
by cytochrome P-450. The present study attempted to demonstrate the 
formation of the MDP metabolite cytochrome P-450 complex in the presence 
of these oxidants.
Phenobarbitone-induced microsomes were incubated with 417 yM 
safrole and the various oxidants at concentrations of 0.5-10.0 mM. Of the 
compounds mentioned above or m-chloroperoxybenzoic acid, only cumene 
hydroperoxide was capable of supporting the formation of the 438 nm 
absorption maximum. Furthermore the 427/455 nm spectrum was not 
observed after the addition of Na2S20ij to the microsomal suspension.
4.4. DISCUSSION
The present work has shown that cumene hydroperoxide is 
capable of mediating the metabolism of MDP compounds, resulting in the 
formation of the characteristic MDP metabolite-cytochrome P-450 complex.
Further evidence is presented to indicate that the 438 nm 
and 427/455 nm spectra are the optical manifestations of similar MDP 
metabolite-cytochrome P-450 complexes, which differ only in their redox 
state.
The reason for NalO^, H2O2 and tfz-chloroperoxybenzoic acid 
being unable to mediate the formation of the MDP metabolite-cytochrome 
P-450 complex is unknown. However, since Hrycay et al. (1975) have 
demonstrated that the relative degrees of 6$-, 7a- and 16a-hydroxylation 
of androstenedione were dependent upon the hydroxylating agent used; it is 
possible that a similar specificity exists for MDP compounds.
The work of Rahimtula et al. (1974) indicated the possible 
participation of higher valence states of cytochrome P-450 in mixed 
function oxygenation reactions, and that the ternary complex of 
reduced cytochrome P-450, oxygen and substrate may have various 
electronic configurations ranging from Fe2+0£ to Fe^+0£lf” (Fig. 4.6.).
Studies with cumene hydroperoxide have indicated that the "activated 
oxygen" species may be the perferryl ion (Fe5+02If ) (Rahimtula et al. , 1974) . 
This complex is analogous to Compound I of peroxidase (Yamazaki et al., 1973).
Cytochrome P-450 has been shown to act as a dioxygenase in 
the peroxidation of polyunsaturated lipids in the presence of organic 
hydroperoxides (O'Brien and Rahimtula, 1974). The mechanism of this 
reaction is believed initially to involve the peroxidase nature of cytochrome 
P-450 (Hrycay and O'Brien, 1972? 1974) with the polyunsaturated lipid as 
the donor, followed by an oxygen dependent chain reaction. Extending 
this hypothesis, it is conceivable that a monooxygenation product may arise 
from a dioxygenation reaction catalysed by cytochrome P-450 (resulting in 
the formation of a substrate hydroperoxide) , followed by a peroxidation 
reaction causing the hydroperoxide intermediate to be reduced to the 
hydroxylated product and water. A hydroperoxide intermediate has been 
demonstrated for the metabolism of fluorene (Benkert et al., 1975) .
By analogy with this situation it is possible that during the mixed 
function oxygenation of MDP compounds a hydroperoxide moiety is introduced 
into the methylene bridge:-
by cumenyl
radical or or cumene hydro-
"active oxygen" peroxide
FIGURE 4.6.
Proposed Mechanism for Monooxygenation Reactions 
Via Cytochrome P-450
RH
3 +
2 +
Fe2+---R H(c)
(a)
(b)
RH, siabs trate
XOOH, organic hydroperoxide
ROH, hydroxylated substrate
(a) may exist in multiple valance states
from Fe2+02 to Fe6+02l+’*
(b) may exist in multiple foonns, from
Fe +02~ to Fe5+02lf“
It is chemically possible that the MDP hydroperoxide may 
spontaneously decompose into the catechol and carbon dioxide or formate. 
However under certain conditions it is also possible that the hydro­
peroxide may decay leading to the formation of H2O2 and the methylene 
carbene:
°\^ I + H2O2
0
The carbene would then be available to bind to the haem of 
cytochrome P-450 as discussed previously (Chapter 3).
The ability to generate the MDP metabolite-cytochrome P-450 
complex using cumene hydroperoxide sheds some lights upon the position of 
the complex in the cyclic scheme for cytochrome P-450 reactions. Using a 
combination (Fig. 4.6.) of the schemes described by Rahimtula et al. (1974), 
Estabrook et al. (1975) and Hrycay et al. (1975), one may postulate that the 
MDP metabolite-cytochrome P-450 complex must be after the formation of 
the perferryl complex in the cumene hydroperoxide-mediated reaction 
sequence. Similarly since NADH synergised the formation of the 455 nm 
absorption peak (Chapter 3) in the NADPH supported reaction, the complex 
must be formed after the addition of the second electron.
Data presented later (Chapter 5) demonstrates that the 
MDP metabolite-cytochrome P-450 complex is produced in vivo and is also 
easily dissociated by excess safrole when in the oxidized but not 
reduced state. Hence the haemoprotein complexes (c) and (d) indicated in 
Fig. 4.6. are of questionable physiological relevance. Since the 
preservation of the MDP metabolite complex in vivo suggests that it remains 
essentially in the ferrous state.
Further information as to the exact nature of the 438 nm 
absorbing complex and its position in the reaction sequence awaits 
experiments utilizing EPR techniques to determine the electronic 
configuration of the haem iron and its ligands.
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5.1. INTRODUCTION
Parke and Rahman (1971) demonstrated.an apparent induction 
of cytochrome bs and the appearance of an absorption maximum at 455 nm 
in the Na2S£0it difference spectrum of hepatic microsomes obtained from 
rats pretreated with safrole or isosafrole. These authors proposed 
that this novel spectrum indicated the induction of a new microsomal 
haemoprotein.
Parke and Gray (1973) showed that the binding spectra of 
certain substrates of the microsomal mixed function oxygenase system 
were subject to a time-dependent intensification when the substrates 
were added to microsomes isolated from rats pretreated with safrole.
Considering the existing knowledge of the in vitro 
interactions of MDP compounds with hepatic microsomes, it was decided to 
investigate further the in vivo interactions of safrole and isosafrole 
with cytochrome P-450.
5.2. RESULTS
5.2.1. The Reduced Difference Spectrum of Safrole- and
Isosafrole-microsomes ,
On the addition of a reducing agent (Na2S20i+, NADPH or 
NADH) to a suspension of safrole- or isosafrole-microsomes (i.e. hepatic 
microsomes obtained from rats pretreated with safrole or isosafrole) 
absorption maxima at 427 and 455 nm were observed in the difference 
spectrum (Fig. 5,1.). The addition of a reducing agent to control or 
phenobarbitone-induced microsomes resulted in the appearance of a 427 nm 
absorption peak only, due to the reduction of cytochrome b5» The 
difference spectrum of reduced safrole- or isosafrole-microsomes was 
similar to that obtained after incubation of phenobarbitone-induced 
microsomes with oxygen, NADPH and safrole in vitro (Chapter 3). The 
apparent enlargement of the reduced cytochrome bs spectrum (at 427 nm)
FIGURE 5.1.
Na2S20it Difference Spectra of Control and Safrole-Microsomes
0*03
500 nm400
Safrole-(----) or control- (- - -) microsomes (2 mg ml-1) were
suspended in 66 mM Tris-HCl buffer (pH 7.4) , ' ^ 2820 '^ added to 
the sample cuvette and the spectrum between 350 and 500 nm 
recorded. The 427 nm absorption maximum of the control microsomes 
is due to reduced cytochrome b 5.
is not due to increased cytochrome b5 formation, as claimed by Parke and 
Rahman (1971) , but rather to the formation of the MDP metabolite-cytochrome 
P-450 complex which absorbs at both 427 and 455 nm.
The high stability of this complex is apparent from its 
ability to withstand the procedures involved in isolation of the microsomes 
Further evidence of this extreme stability of the complex was obtained by 
dialysis of safrole-microsomes. 10 ml Safrole-microsomes (2 mg-ml”*) were 
dialysed against 500 ml 66 mM Tris-HCl buffer (pH 7.4) for 6 hours at 4°. 
Other safrole-microsomes were stored in parallel at 4° for 6 hours. The 
cytochrome P-450 contents and the magnitudes of the 455 nm absorption 
maxima (on the addition of Na2S20 )^ were measured before and after dialysis 
When corrected for changes in the protein concentration less than a 
5% decrease in the magnitude of the 455 nm absorbance was incurred due to 
dialysis.
5.2.2. The Displacement Phenomenon
In agreement with Parke and Gray (1973) the present work 
demonstrated that on the addition of certain Type I compounds to oxidized 
safrole- or isosafrole-microsomes a time-dependent intensification of the 
compound's binding spectrum occurs (Fig. 5.2.). Not only did the peak and 
trough increase in magnitude, but the trough underwent a gradual red 
shift from about 420 to 438 nm. This phenomenon is called displacement, 
and compounds which elicit this process are termed displacers or 
displacing substrates.
Many compounds have been tested for their displacing 
abilities; Table 5.1. summarizes these data. It was apparent that none 
of the Type RI or Type II compounds tested elicited this phenomenon.
Some degree of lipophilicity as judged by the log P values was required 
for displacement; however structural and steric parameters appeared just 
as important since piperonyl butoxide, which has a log P value of over 5, 
did not undergo a time-dependent intensification of its binding spectrum.
FIGURE 5.2.
The Time-dependent Enhancement of the Cyclohexane Type I 
Binding Spectrum in Isosafrole-microsomes
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Isosafrole-microsomes were suspended in 66 mM Tris-HCl buffer 
(pH 7.4) to a protein concentration of 1 mg ml""1. A baseline 
of equal light absorbance between 350 and 500 nm was recorded. 
Cyclohexane (208 yM) was added to the sample cuvette and the 
spectrum between 350 and 500 nm repetitively scanned at a 
speed of 5 nm sec-1. Spectra were therefore recorded every 
minute.
The Ability of Various Compounds to Act as Displacers
Compound Binding Spectrum (Type)
—  * 
log P Displacer
ability
ethanol RI 0.32 -
dime thy 1 formami de RI -
cyclohexane I 2.73 +
safrole I 3.18 +
isosafrole I 3.38 +
ethylmorphine I about 1.0 -
biphenyl I 4.09 +
carbon tetrachloride I 2.64 -
freon 11 I .
hexobarbitone I 1.49 +
ethylbenzene I 3.13 +
aniline II 0.94
bipyridyl II
nicotinamide II 1.20
i
n-octylamine II -
piperonyl butoxide I 5.20 -
SKF-525A II -
metyrapone II -
* log P values were kindly calculated by Dr. R. Hyde.
The degree of increase in the binding spectrum of a displacer 
was found to be proportional to the magnitude of the 455 nm absorbance 
originally observed on reduction of the safrole- or isosafrole-microsomes. 
Rats were pretreated for various times (2 days to 3 weeks) with dietary 
safrole to allow the preparation of safrole-microsomes containing varying 
amounts of the 455 nm absorbing safrole metabolite-cytochrome P-450 
complex. Two spectral parameters were then obtained; the magnitude of 
the 455 nm absorption maxima were determined by chemical reduction of the 
microsomes by ^ 2820 ,^ and the degree of enhancement of the Type I spectrum 
of a displacing substrate was measured using safrole itself as the 
displacer. Figure 5.3. indicates the relationship between the magnitude 
of the 455 nm absorbance (when chemically reduced) and the enhancement 
of a displaced Type I binding spectrum. It is apparent that the 
enhancement is directly proportional to the initial concentration of the 
455 nm absorbing complex.
A further experiment clearly demonstrated this relationship. 
Safrole-microsomes were incubated with a Type I displacing substrate 
(e.g. safrole) and after fixed time intervals Na2S20i+ was immediately added 
to the microsomes and the residual 455 nm absorbance measured. (It 
should be emphasized at this point that displacement will not occur 
under reducing conditions in the presence of NADPH, NADH or Na2S20i*) .
The magnitude of the displacer's oxidized Type I binding spectrum at time, t 
was plotted against the magnitude of the 455 nm absorption maximum after 
chemical reduction by Na2S204 at time, t. Figures 5.4. and 5.5. clearly 
indicate that an inverse relationship exists between the magnitudes of the 
455 nm absorbance and the displacers oxidized binding spectrum. As the 
magnitude of the 455 nm absorbance decreases the Type I oxidized binding 
spectrum of the displacer increases. Figures 5.4. and 5.5. represent two 
different displacer concentrations (167 yM and 417 yM respectively); it
FIGURE 5.3.
The Relationship Between the Degree of Spectral Enhancement 
of a Type I Displacer's Binding Spectrum and the Initial 
Absorbance at 455 nm
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Each point represents a different safrole-microsomal preparation 
at a concentration of 2 mg ml-1. Complete displacement was 
effected by the addition of 833 yM safrole, and the initial and 
final Type I displacer spectra recorded (AA peak-trough).
Parallel samples were reduced with Na2S20i4 to determine the initial 
absorbance at 455 nm.
FIGURE 5.4.
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The Correlation Between Increase of Safrole (Displacer) Type 
I Binding Spectrum and Decrease of 455 nm Absorption
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Safrole-microsomes (1 mg ml”1) in 66 mM Tris-HCl buffer (pH 7.4) 
were divided between two cuvettes. 167 yM safrole was added to 
sample cuvette at zero time. The spectrum between 500 and 350 nm 
was recorded every 2 minutes and the sample cuvette reduced with 
Na2S20i+ at suitable times. Number of experiments = 15.
Development of Type I safrole (displacer) binding spectrum 
with time
AA = peak-trough
♦, Magnitude of 455 nm absorption measured after addition 
of Na2S20t+ to sample cuvette at certain times
AA = 455-490 nm.
FIGURE 5.5.
The Correlation Between Increase of Safrole (Displacer) Type 
I Binding Spectrum and Decrease of 455 nm Absorption
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Safrole-microsomes (1 mg ml-*) in 66 mM Tris-HCl buffer (pH 7.4) 
were divided between two cuvettes. 417 yM safrole was added to 
sample cuvette at zero time. The spectrum between 500 and 350 nm 
was recorded every 2 minutes and the sample cuvette reduced with 
Na2S20if at suitable times. Number of experiments = 12.
o ----- o, Development of Type I safrole (displacer) binding
spectrum with time
AA = peak-trough
0   ---  ©, Magnitude of 455 nm absorption measured after addition
of Na2S20i| to sample cuvette at certain times
AA = 455-490 nm.
is immediately apparent that the rate of displacement is dependent upon 
the concentration of displacing substrate.
This relationship is exemplified in Fig. 5.6., where 
a range (41.7-417 yM) of displacer concentrations was employed. Not only 
did the rate of displacement (as measured by the rate of increase in the 
displacer's binding spectrum) increase with increasing displacer 
concentration but the final magnitude of the displacer's binding 
spectrum appeared to change. Because of the inaccuracies encountered in 
attempting to quantify the final change in the magnitude of the displacer's 
binding spectrum using the plot illustrated in Fig. 5.6., a double 
reciprocal plot was constructed of A^peak-trough (for displacer's 
binding spectrum) versus time (since this type of plot lends itself to 
more accurate estimations' of AAmax). Figure 5.7. indicates that the 
magnitude of the final change in the displacer's binding spectrum (AAfinai) 
varies according to the concentration of displacing substrate.
The affinity of the displacer (in this case safrole) for 
safrole-microsomes before and after displacement was calculated utilizing 
double reciprocal plots of AApg^.. trough vevsus displacer concentration 
(Fig. 5.8.). The AAf^na]_ varies according to the concentration of 
displacing substrate.
The affinity of the displacer (in this case safrole) for 
safrole-microsomes before and after displacement was calculated utilizing 
double reciprocal plots of AApe^ trough versus displacer concentration 
(Fig. 5.8.). The AAf^na  ^values were obtained from the y intercepts on 
Fig. 5.7., and the ^Aj_n^tial va-*-ues were obtained by extrapolation of the 
curves in Fig. 5.6. to zero time. A distinct difference was noted between 
the initial and final Ks values for safrole as a displacer (Fig. 5.8.). 
These Ks values were 46 and 130 yM respectively.
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FIGURE 5.6.
The Effect of Safrole (Displacer) Concentration on the 
Enhancement of the Safrole Type I Binding Spectrum
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Conditions as Fig. 5.4. Safrole (displacer) concentration: 
@417 yM; □, 167 yM; ©, 83.3 yM; Q, 41.7 yM. AA = peak-trough.
FIGURE 5.7.
Double Reciprocal Plot for Time-dependent Increase 
of Safrole Type I Binding with Safrole microsomes.
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•Conditions as Fig. 5.4. Safrole (displacer) con­
centrations: A/ 41.7 yM; H, 62.5 yM; A, 83.3 yM; 
O, 167 yM; ©, 417 yM. AA = peak-trough.
FIGURE 5.8.
Ks (Initial and Final) Plots for Safrole (Displacer), 
Type I binding with Safrole microsomes
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Conditions as Fig. 5.4. Curves are shown 
for 2 representative safrole-microsomal 
preparations (Q and ©) .
The results presented so far in this Chapter indicate that 
certain Type I substrates may cause the dissociation of the MDP metabolite- 
cytochrome P-450 complex when added to oxidized safrole- or isosafrole- 
microsomes. Extending this hypothesis, the intensification of the Type I 
displacer's binding spectrum could be explained by more displacer being 
able to bind to the uncomplexed haemoprotein. This basic hypothesis is 
supported by data obtained by Dickins (personal communcation), who has 
demonstrated the competitive inhibition of Type I substrate (safrole 
or cyclohexane) binding to cytochrome P-450 by imidazole (a Type II 
compound). The MDP metabolite appears to interact at the same site of 
cytochrome P-450 as Type II compounds (i.e. the haem moiety). Hence 
while the MDP metabolite remains bound to the cytochrome P-450, the 
binding of Type I compounds will be competitively inhibited. However when 
the MDP metabolite complex is dissociated more Type I compound is able to 
bind to the cytochrome, thus an increased Type I binding spectrum of the 
displacer would be observed. This competitive inhibition of displacer 
Type I binding could explain the difference in the Ks value of safrole 
before and after displacement (Fig. 5.8.).
This simple explanation is not the entire mechanism of 
the displacement phenomenon; since if the enhanced binding spectrum was 
merely the binding of further amounts of Type I substrate, then 
the wavelength of the absorption minimum of the spectrum should be 
unchanged. However, as can be seen in Fig. 5.2. for cyclohexane and Fig.
5.9. for safrole, the position of the spectral trough moved from about 420 nm 
to about 438 nm. A probable explanation for this observation may be 
derived from in vitro observations (reported in Chapter 3) where it was 
shown that the MDP metabolite-cytochrome P-450 complex has an absorption 
maximum at 438 nm in the oxidized state. Hence the baseline of equal 
light absorbance in Fig. 5.9. is obtained because the 438 nm absorption
FIGURE 5.9.
Safrole as a Displacer in Isosafrole microsomes
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Isosafrole microsomes (6 ml) were suspended to a protein concentration 
of 1 mg ml“* in 66 mM Tris-HCl buffer (pH 7.4). The microsomes were
divided between two cuvettes and a baseline of equal light absorbance
between 350 and 500 nm obtained. Safrole (208 yM) was added to the
sample cuvette, and the spectrum between 350 and 500 nm recorded
every minute.
maximum of safrole-microsomes is present at the same concentration in both 
cuvettes. On the addition of a Type I displacing substrate (e.g. safrole 
or cyclohexane) to the sample cuvette a small initial Type I binding 
spectrum is observed, due to the Type I compound binding to uncomplexed 
haemoprotein. Then a time dependent dissociation of the 438 nm absorbing 
MDP metabolite-cytochrome P-450 complex occurs in the sample cuvette, but 
not the reference cuvette. Hence, since a loss of absorbance at 438 nm 
occurs in the sample cuvette but not in the reference cuvette, a trough is
observed at 438 nm in the difference spectrum. This explanation is
summarized in Table 5.2.
The increase in absorbance at 390 nm may be explained by 
the competition between the MDP metabolite and the Type I compound for 
binding to oxidized cytochrome P-450. However since more Type I compound 
becomes bound to the haemoprotein during the displacement process why 
does the absorbance at 420 nm remain unchanged? For one might expect a 
dual trough with minima at 420 and 438 nm, but as can be seen in Fig. 5.9. 
this does not occur, 420 nm is actually an isosbestic point. The 
explanation for the existence of this isosbestic point is derived from Fig.
5.10., where it can be seen that the MDP-metabolite complex with
oxidized cytochrome P-450 has a trough at 420 nm in addition to the peak 
at 438 nm. Hence during displacement, as the 438 nm absorbance decreases 
the 420 nm absorbance increases. This increase of light absorbance at 
420 nm is fortuitously cancelled out by the decrease at 420 nm due to the 
low to high spin transition of the cytochrome on the binding of the Type I 
substrate (displacer). This complete interpretation of the spectral 
changes which accompany the displacement phenomenon is summarized in 
Fig. 5.11.
An Explanation for the Red Shift in the Trough of 
a Displacer's Type I Binding Spectrum
Reference Cuvette Sample Cuvette Difference Spectrum
Safrole-microsomes, with 
the 438 nm absorbing 
complex present
as in the reference 
cuvette
Baseline
Solvent alone added Displacer + solvent 
added
Type I spectrum 
observed immediately
438 nm absorbing 
complex remains 
unchanged
438 nm absorbing 
complex gradually 
dissociated with time
trough at 438 nm 
gradually increases 
with time
Reference and sample cuvette descriptions indicate additions to and 
reactions occurring in the cuvettes. Difference spectrum refers to 
the spectrum observed utilizing the split beam mode of measurement.
FIGURE 5.10.
The In V'itvo Generated 438 nm Absorbing Complex 
and Its Dissociation.' ■
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Phenobarbitone-induced microsomes (6 ml) suspended to a protein 
concentration of 1 mg ml-1 in 66 mM Tris-HCl buffer (pH 7.4) were 
divided between two cuvettes. A baseline of equal light absorbance 
was obtained, and safrole (208 yM) was added to the sample cuvette 
and NADPH to both cuvettes. After formation of the 427/455 nm 
absorbing spectrum (Chapter 3), glutamate dehydrogenase, NHi+Cl, 
and a-oxoglutarate were added to both cuvettes to oxidize the NADPH. 
The 438 nm spectrum of the oxidized MDP metabolite complex was then 
observed over a period of 10 min. The recordings'were made at 30 
second intervals at a scan speed of 10 nm sec” .^ The arrows indicate 
the change in the peak and trough.
Diagramatic Explanation of the Spectral Changes 
Observed during the Displacement Process
Sample
Cuvette
Reference
Cuvette
Difference
Spectrum
380 460 380420
Wavelength (nm)
420 460 380 420 460
Initially (A) the difference spectrum is a flat baseline, 
since the MDP metabolite complex (with a trough at 420 nm 
and a peak at 438 nm) is present at the same concentration 
in both cuvettes. On the addition of a displacer to the 
sample cuvette (B) an immediate Type I spectrum is observed 
in the difference spectrum (due to an increase at 390 run 
and a decrease at 420 nm in the sample cuvette). With 
increasing time the MDP metabolite complex is dissociated 
in the sample cuvette but not in the reference (C) . Hence 
the difference spectrum gradually increases in absorbance 
at 390 nm (due to more Type I substrate binding) and decreases 
in absorbance at 438 nm (due to dissociation of the 438 nm 
absorbing complex in the sample cuvette but not in the 
reference cuvette. In the difference spectrum an isosbestic 
point is observed at 420 nm because in the sample cuvette 
the dissociation of the complex leads to an increase in 
absorbance at 420 nm, while binding of more Type I substrate 
(displacer) causes a decrease in absorbance at 420 nm.
These two phenomena appear to be mutually cancelling.
It is apparent that the observed time dependent intensification
of a displacing agent's binding spectrum is the suiii of two associated events;
the dissociation of the 438 nm absorbing complex and the subsequent binding
of more Type I compound (the displacer). Hence the kinetic analysis of
displacement detected earlier, being based on AA ,  ^ , values of thepeak-trough
displacer's binding spectrum, is indirect and not absolute. I have
therefore examined the kinetics of the displacement phenomenon utilizing
measurements of the rate of decrease in absorbance at 438 nm. In this
situation the dissociation of the MDP metabolite complex with oxidized
cytochrome P-450 is observed directly. The decrease of absorbance at
438 nm was measured with respect to 475 nm which was found to be an
isosbestic point. A double reciprocal plot was constructed of AA^33-475
versus time (Fig. 5.12.) in a similar manner to that drawn for the
trough Va^U0S t*ie displacer's binding spectrum (Fig. 5.7.). A distinct
difference was observed between these two graphs. The plot depicting
AA ,  ^ -1 versus time”"* revealed different final AA values atpeak-trough
different concentrations of displacer, however when AA43q_475 was plotted
in similar manner the final AA values were identical irrespective of the
concentration of displacer. This is further evidence for the displacement
phenomenom being due to the dissociation of a safrole metabolite-cytochrome
P-450 complex which has an absorption maximum at 438 nm in the oxidized
state. Since in this situation one would expect the time taken to
complete the reaction, but not the magnitude of the final change in
AA^38-475t to be dependent on the displacer concentration. However
the final AA , , . values are a summation of a trough of constantpeak-trough
magnitude at 438 nm, and a peak (390 nm) and trough (420 nm) which vary in 
magnitudes depending upon the concentration and Ks value of the displacing 
Type I substrate.
FIGURE 5.12.
Double Reciprocal Plot for the Time-dependent Change in 
the Absorbance at 438 nm during the Displacement Process
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Conditions as in Fig. 5.4. ^-1+38-475 was measured by
repetitive scanning at 30 second intervals.
The Type I compound-induced dissociation of the MDP 
metabolite-oxidized cytochrome P-450 has been confirmed using *4C- 
isosafrole. Hepatic microsomes were prepared from rats pretreated with 
l^C-isosafrole (150 mg kg-1; 1.25 mCi mmole-*) by intraperitoneal 
injection daily for 4 days. The ll+C-isosafrole-microsomes were diluted 
to approximately 1 mg ml~* and divided into two aliquots of 10 ml.
Samples (3 ml) of each suspension were taken for the determination of 
protein and radioactivity. Cyclohexane (6 yl) was added to one portion 
of the microsomes (Test) and both aliquots of microsomes then incubated 
at 37° for 1 hour. After this time the microsomal suspensions were 
dialysed individually against 300 ml of 66 mM Tris-HCl buffer (pH 7.4) 
at 4° for 16 hours. The volumes of the diffusate and non-diffusible 
materials were measured prior to the determination of protein: and 
radioactivity, in order to determine the exact concentrations of *^C- 
isosafrole-related material and protein. The magnitude of the absorption 
maximum at 455 nm was determined in the test and control ^C-isosafrole- 
microsomal suspensions both before and after the incubation and dialysis.
The results of this experiment are shown in Table 5.3. It is clear that 
a considerable quantity of ll+C-isosafrole related material was displaced 
from the ^C-isosafrole-microsomes during incubation with cyclohexane.
It is unlikely that this was a solvent effect, since the concentration of 
cyclohexane was only 0.857 yl ml-1 (less than 10 mM), and a similar 
experiment substituting 25 mM dimethylformamide (which is not a displacer) 
for the cyclohexane did not demonstrate any displacement of radioactivity.
The total loss of ^C-isosafrole—related material from the 
microsomes due to cyclohexane displacement (i.e. radioactivity lost from 
test minus radioactivity lost from control) was 15,906 dpm or 7.164 nCi.
This was equivalent to a total of 5.731 nmol of isosafrole (equivalent to 
0.6629 nmol isosafrole related material displaced per mg microsomal protein).
The Displacement of Reversibly Bound ^C-isosafrole-related 
Material from ll|C-isosafrole-Microsomes
Microsomes 
+ cyclohexane as displacer
Microsomes
alone
Original radioactivity, (A) 
(total dpm)
66,092 66,092
Radioactivity remaining in 
microsomes after dialysis, (B) 
(total dpm)
37,427 53,333
Therefore loss of activity from 
microsomes during dialysis, (A-B) 
(total dpm)
28,665 12,759
Radioactivity in diffusate, (C) 
(total dpm)
29,040 13,752
Recovery of radioactivity
H *  - ™  I
100.6% 101.5%
Loss of radioactivity from 
microsomes
i
43.4% 19.3%
AEi+55_t+9Q per mg protein
originally
after displacement
0.0486
0.0020
0.0486
0.0462
Recovery of protein 100.1% 98.1%
The amount of complexed cytochrome P-450, as determined by 
the method of Omura and Sato (1964a), before and after the displacement 
process, was 0.611 nmol mg”1 protein (assuming an extinction coefficient 
for the carbon monoxide complex of 91 mM_1cm“^).
It therefore appears that the "displaceable isosafrole- 
related material" and the haemoprotein of the MDP metabolite-cytochrome 
P-450 complex were in a ratio of 0.6629:0.611 (1.08:1). Hence the 
complex appeared to be equimolar in haemoprotein and MDP metabolite.
Extinction coefficients were calculated from the spectro- 
photometric and radiometric data. Since 0.6629 nmol of isosafrole- 
related material were bound to cytochrome P-450 resulting in a AA^ 55-1*90 
of 0.0486 extinction units, the calculated extinction coefficient of the MDP 
metabolite complex is 0.0486A/0.6629 yM which equals 0.0733 yM“1 cm”1. The 
extinction coefficient of the complex was also calculated from the 
difference in the measureable concentration of cytochrome P-450 (as 
measured by its carbon monoxide complex) before and after dissociation 
of the MDP metabolite complex. Thus, 0.611 AAi*50-1*90 Per m9 protein was 
the amount of cytochrome P-450 complexed with the MDP metabolite, therefore 
0.611 nmol cytochrome P-450 was equivalent to 0.0486AAi*5'5_ifgQ (since the 
cytochrome P-450 contents of the carbon monoxide and MDP metabolite 
complexes were identical). Therefore the extinction coefficient of the 
MDP metabolite complex is 79.5 mM“1cm” .^ These values are similar to 
the extinction coefficients for the amphetamine metabolite complexes with 
cytochrome P-450 (65 mM-*cm”*) quoted by Franklin (1974b).
Similar experiments have been carried out using centrifugation 
and washing procedures instead of dialysis. Isosafrole-microsomes were, 
incubated with a displacing compound as indicated above. The microsomes 
were then sedimented by centrifugation and washed twice by resuspension in 
1.15% (w/v) KC1 and further centrifugation, and finally resuspended in 66 mM
Tris-HCl buffer (pH 7.4) to the original protein concentration. The
magnitude of the Na2S20i* reducible 455 nm absorbance and the amount of 
radioactivity in the diffusible and non-diffusible materials were measured. 
The results obtained in these experiments confirmed those described earlier 
using the dialysis technique.
5.2.3. Displacement After Formation of the 427/455 nm
Absorbing Species In Vitro
Several attempts have been made to demonstrate the displacement 
phenomenon after formation of the MDP metabolite-cytochrome P-450 complex 
in vitro. The complex was produced in control and phenobarbitone-induced 
microsomes by incubation with safrole (417 yM), NADPH (200 yM) and oxygen 
for 20 minutes at 37°C. The microsomes were then dialysed for 4 hours at 4° 
against 66 mM Tris-HCl buffer (pH 7.4) or centrifuged and washed with 1.15% 
KCl to remove excess substrate and cofactor. However after this procedure 
not even an initial binding spectrum was elicited on the addition of 
safrole, biphenyl or cyclohexane. Hence it appears that the proportion 
of cytochrome P-450 in control or phenobarbitone-induced microsomes 
capable of binding substrate was totally complexed to the safrole metabolite.
The complex was also produced using cumene hydroperoxide as 
the source of "active oxygen" and then subjected to the washing procedures 
as above, but still no binding spectrum could be obtained after the 
addition of a Type I substrate. The inability to observe a Type I binding 
spectrum subsequent to the washing procedures was not due to denaturation 
of the haemoprotein, since control or phenobarbitone-induced microsomes 
incubated with NADPH or cumene hydroperoxide (in the absence of safrole) 
were still able to bind Type I substrates after washing.
The present study (Chapter 6) has demonstrated that safrole 
and isosafrole induce a novel haemoprotein, whose properties are more 
similar to cytochrome P-448 than cytochrome P-450. I therefore decided to 
attempt the dissociation of the in vitro generated MDP metabolite complex 
in microsomes from animals pretreated with 20-methylcholanthrene or a
combination of 20-methylcholanthrene and phenobarbitone (phenobarbitone 
80 mg kg-1 for 3 days; 20-methylcholanthrene 30 mg kg-1 for 1 day; 
animals killed on fourth day). The MDP metabolite complex was generated 
in these microsomes by incubation with safrole and NADPH, and the 
microsomes were then washed by dialysis (as above) and the Type I 
binding spectra of safrole, cyclohexane and biphenyl determined. Once 
again the displacement phenomenon encountered in safrole-microsomes was 
not observed.
5.3. DISCUSSION
Evidence has been presented for the formation of an 
equimolar complex of a MDP metabolite with cytochrome P-450 in vivo.
This complex has a high stability as witnessed by its preservation after the 
isolation procedures involved in the preparation of microsomal fractions 
and prolonged dialysis.
Despite the high stability of this complex it is may be 
dissociated with ease in the presence of certain Type I substrates. This 
dissociation only occurs under oxidized conditions, the presence of 
displacers has no effect when the cytochrome P-450 is in the ferrous state..
The displacement phenomenom was shown to involve the initial 
binding of a Type I substrate to the haemoprotein followed by the time 
dependent dissociation of the MDP metabolite-cytochrome P-450 complex 
with expulsion of the metabolite into solution.
This displacement process could not be demonstrated after 
in vitro formation of the MDP metabolite complex. Hence it seems that 
the displacement phenomenom is unique to microsomes obtained from animals 
pretreated with MDP compounds, and therefore is probably dependent on the 
presence of a novel cytochrome. Experiments described earlier demonstrated 
that the displacement process did not occur after the formation of the 
MDP metabolite complex with cytochrome P-448 or a mixture of cytochromes P-448 
and P-450.
The presence of a newly induced cytochrome in safrole- 
microsomes is also suggested on the basis of different initial and final 
Kg values for safrole with safrole microsomes, before and after displacement. 
It is likely that the initial Ks value of the safrole as displacer refers 
to the "free" cytochrome (i.e. not complexed with the MDP metabolite) , while 
the final Ks value represents a combination of binding of the displacer to 
"free" and "released" cytochrome. Possibly the "free" cytochrome is a 
newly induced cytochrome of the P-448 class (plus perhaps some P-450) and 
that after displacement a mixture of "old" cytochrome P-450 and "new" 
cytochrome P-448-like haemoprotein is available to interact with the 
displacer (cytochrome P-448 in this context does not mean that the cytochrome 
P-448 induced by safrole is identical to that induced by 20-methylcholanthrene) 
This concept shall be developed further in a later chapter.
An outstanding problem is the inability to demonstrate the 
displacement process after generating the MDP metabolite-cytochrome P-450 
complex in vitro. Since the mechanism of the displacement process is 
unknown hypotheses must necessarily be in vague terms. However it would 
appear that the initial step in the displacement process is a conformational 
change, induced by the displacing substrate, of the complexed haemoprotein 
or a neighbouring cytochrome molecule. This conformational adaptation may 
alter the molecular environment of the haem moiety in the haemoprotein 
resulting in the formation of a thermodynamically unfavourable transition 
state complex which dissociates into a MDP metabolite and the free haemo­
protein. The MDP metabolite which is released into solution is probably 
not the same metabolite which was initially bound to the haemoprotein. For 
example, if the active metabolite was a carbanion (Ullrich and Schnabel,
1973) then the "displaced metabolite" may be safrole itself, due merely to
a reprotonation process. This type of displacement phenomenon may be 
capable of explaining the unusually long reaction times (up to 1 hour 
depending upon displacer used and its concentration), since a reprotonation 
reaction would not be favourable within a hydrophobic environment such as 
that encountered in the microsomal membranes. However if the active 
metabolite is a carbene (Chapter 3) it is difficult to envisage the 
mechanism of displacement in similar terms.
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6.1. INTRODUCTION
Safrole and isosafrole have been shown to be inducers of 
hepatic and extrahepatic drug metabolizing enzymes (Parke and Rahman,
1970; Lotlikar and Wasserman, 1972; Lake, 1974; Gray, 1975). The 
data of Lake and others (1973; 1974) indicated that the "pattern of 
induction" (with respect to substrates) elicited by safrole and isosafrole 
is similar to that obtained using 20-methylcholanthrene. This is 
demonstrated clearly in Table 6.1. (from Lake, 1974). Benzopyrene 
hydroxylation was markedly increased by 20-methylcholanthrene or 
isosafrole but not by phenobarbitone. The extent to which the 2- and 
4-hydroxylations of biphenyl are stimulated may be used as a sensitive 
test for the type of inducer acting (Creaven, Parke and Williams, 1965). 
Phenobarbitone preferentially induces the 4-hydroxylation while polycyclic 
hydrocarbons stimulate the 2-hydroxylation of biphenyl. Table 6.1. 
indicates that isosafrole stimulated the 2-hydroxylation to a similar 
extent to 20-methylcholanthrene and the 4-hydroxylation to the same 
degree as phenobarbitone. Hence, in general, stimulation by isosafrole 
and safrole leads to a metabolic induction pattern which has characteristics 
of both the barbiturate and polycyclic hydrocarbon classes of inducing 
agents.
Preliminary investigations based on the spectral nature of 
the haemoprotein induced by isosafrole and safrole suggested that it was 
cytochrome P-448 (Elcombe et al., 1975). However evidence presented in 
this Chapter indicates that the safrole-induced cytochrome is similar 
but not identical to cytochrome P-448. Because of the inducing 
properties of safrole and isosafrole it was also decided to investigate 
the effect of other inducers on the formation of the MDP-metabolite- 
cytochrome P-450 complex in vitro.
The "Induction Profile" due to various Inducing Agents (Lake, 1974)
Inducing ^gent
Reaction Studied
*
PB 20-MC** Isosafrole
Benzpyrene hydroxylase 105 515 215
. Biphenyl-2-hydroxylase 230 620 540
Biphenyl-4-hydroxylase 250 160 245
Aniline-4-hydroxylase 160 70 65
Acetanilide-4-hydroxylase 150 220 195
4-chloro-i7-me thy lani line 
demethylase
125 160 190
4-nitroanisole
demethylase
155 165 125
Cytochrome P-450 content 250 170 150
* Phenobarbitone; ** 20-methylcholanthrene.
Results are expressed as the percentage difference from 
those obtained using microsomes from un-induced animals
6.2. METHODS
When high resolution spectra were required an Aminco DW2 
spectrophotometer was used. A scanning speed of 0.1 nm sec** and a slit 
width (band pass) of 1.0 nm were employed to enable the accurate 
determination of the wavelength maxima and minima.
w-Octylamine difference spectra were measured by the method 
of Jefcoate, Calabrese and Gaylor (1970), using yl quantities of a 250 mM 
stock solution of n-octylamine in dimethylformamide.
Hepatic microsomes from patas and rhesus monkeys, rainbow 
trout and dogs were prepared as described earlier for rats. Microsomes 
from the small intestines of rats were kindly provided by Mr. R. Shirley.
6.3. RESULTS
6w3.1. Spectral Characteristics of the Safrole-induced Microsomal
Haemoprotein(s)
The complex of carbon monoxide with reduced cytochrome P-450
in control or phenobarbitone-induced microsomes was found to have an
absorbance maximum at 450.8 nm. However after four weeks treatment
of rats with dietary safrole, a blue shift to 449.9 nm in the maximum of
the carbon monoxide complex was observed (Table 6.2.). 20-Methylcholanthrene- 
induced microsomes, after reduction with Na£S20if, reacted with carbon 
monoxide resulting in the observation of an absorbance at 449 nm. Hence 
the absorption maximum of the carbon monoxide complex with safrole- 
induced microsomes was about 1 nm away from that in control, phenobarbitone- 
induced or 20-methylcholanthrene-induced microsomes. Therefore it appears 
that the haemoprotein induced by safrole is neither cytochrome P-450 nor 
cytochrome P-448 (Pi-450). The apparent concentration (as measured by the 
carbon monoxide spectrum) of the haemoprotein in safrole-microsomes was 
only slightly higher than that in control microsomes. However since the 
safrole metabolite-cytochrome complex was also present, the true
haemoprotein concentration was considerably higher.
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The blue shift in the absorbance maximum of the carbon 
monoxide complex of safrole-microsomes was not due to the presence of 
the safrole metabolite-cytochrome P-450 complex, since after dissociation 
of the complex (Chapter 5) the wavelength maximum of the carbon monoxide 
complex was unchanged. Furthermore after generation of the safrole 
metabolite-cytochrome P-450 complex in vitro, from safrole, NADPH and 
control microsomes, and subsequent treatment of the microsomes with 
carbon monoxide, a shift in the absorbance maximum of the carbon monoxide- 
cytochrome P-450 complex was not observed.
Jefcoate et al. (1970) have proposed the use of the 
n-octylamine microsomal difference spectrum as an indicator for the 
presence of cytochrome P-450 or cytochrome P-448. The present study 
showed that the position of the peak around 430 nm in the n-octylamine 
difference spectrum altered depending upon the pretreatment of the 
animals. In control microsomes the peak was found at 430.2 nm, whereas 
in phenobarbitone- and 20-methylcholanthrene induced microsomes it was 
at 431.0 and 428.5 nm respectively. After induction with safrole 
the n-octylamine peak was shifted to 428.9 nm, a position approaching 
that found in 20-methylcholanthrene-induced microsomes.
The most striking characteristic of safrole-microsomes was 
the magnitude of the n-octylamine spectrum. When calculated on the basis 
of cytochrome concentration (i.e. magnitude per nmol, cytochrome) the 
n-octylamine difference spectrum was greatly increased in safrole- 
microsomes (Table 6.2.) when compared with control, phenobarbitone- or 
20-methylcholanthrene-induced microsomes.
Similar spectral measurements were made on microsomes 
obtained from animals fed dietary safrole for four weeks and then returned 
to a normal diet for four days before sacrifice (Table 6.3.).
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The absorbance maximum of the carbon monoxide complex in 
these microsomes had reverted to 450.3 nm (approaching the control value), 
suggesting that the microsomal haemoprotein population was reverting to 
normal in the absence of the exogenous inducing agent safrole. Furthermore 
both the position of the absorbance maximum and the magnitude of the 
n-octylamine spectrum had reverted to control values. At this point it 
is of interest that the large amount of the 455 nm absorbing safrole 
metabolite-cytochrome P-450 complex observed earlier (Table 6.2.) had 
disappeared after return of the animals to a normal diet for four days.
6.3.2. The Formation of the MDP metabolite-cytochrome P-450
Complex in variously Induced Microsomes
The in vitro formation of the MDP metabolite-cytochrome P-450 
complex was dramatically affected by pretreatment of the animals with 
inducing agents. With phenobarbitone-induced or control microsomes a 
427/455 ratio of approximately 2:1 was obtained at a safrole concentration 
of 208 yM (Fig. 6.1.). When 20-methylcholanthrene-induced microsomes were 
incubated with 208 yM safrole and NADPH in the presence of oxygen, only 
the 455 nm absorption maximum was seen (Fig. 6.2.). The 427 nm peak did 
not appear even after prolonged incubations with NADPH and the subsequent 
addition of Na2S20if. The incubation of microsomes, obtained from rats 
pretreated with both phenobarbitone (80 mg kg-1 for three days) and 20- 
methylcholanthrene (30 mg kg“* for one day), with safrole and NADPH 
resulted in a spectrum with a 427/455 ratio of about 1:2 (Fig. 6.3.).
This spectrum was clearly a simple summation of the spectra shown in 
Figs. 6.1. and 6.2.
The Km value for the formation of the 455 nm absorbing
\
species was found to alter after induction. The Km values were 18 and 83 yM 
in phenobarbitone- and 20-methylcholanthrene-induced microsomes respectively. 
Noteworthy is that these values correspond to the differences in the K£ 
values of safrole with phenobarbitone- and 20-methylcholanthrene-induced 
microsomes (18.5 and 80 yM respectively).
FIGURE 6.1.
Formation of the Safrole Metabolite-cytochrome P-450 Complex
in Phenobarbitone-induced Microsomes
0*005 A
nm
450 490
Phenobarbitone-induced microsomes (6 ml) suspended in 66 mM 
Tris-HCl buffer (pH 7.4) to 1 mg protein ml were divided 
between two cuvettes. A baseline of equal light absorbance 
was constructed, then safrole (208 yM) was added to the 
sample cuvette and the difference spectrum recorded (-©-©-). 
NADPH (200 yM) was added to both cuvettes and the spectra 
recorded every 30 seconds. Representative scans are 
numbered.
FIGURE 6.2.
Formation of the Safrole Metabolite-cytochrome P-450 Complex
in 20-Methylcholanthrene-induced Microsomes
0 005 A
410 450 490
nm
Conditions were as described in Fig. 6.1., except 20-methyl­
cholanthrene-induced microsomes (1 mg ml-1) were used.
FIGURE 6.3.
Formation of the Safrole Metabolite-cytochrome P-450 Complex
in Phenobarbitone/20-Methylcholanthrene-induced Microsomes
0 *0 0 5  A
nm
430 450 470 4 9 0
Conditions were as described in Fig. 6.1., except microsomes 
(1 mg ml”*) obtained from animals pretreated with both pheno­
barbitone and 20-methylcholanthrene were used.
This phenomenon involving the absence of the 427 nm 
peak in 20-methylcholanthrene-induced microsomes was also observed with 
other MDP compounds. For example as shown in Fig. 6.4. the formation of 
the 455 nm absorbing species from methylenedioxybenzene and 20-methyl­
cholanthrene-induced microsomes, was also unaccompanied by an absorbance 
maximum at 427 nm.
The present work also investigated the cumene hydroperoxide 
mediated formation of the safrole metabolite-cytochrome P-450 complex. As 
described earlier, the incubation of phenobarbitone-induced microsomes 
with safrole and cumene hydroperoxide resulted in the time-dependent 
formation of an absorption maximum at 438 nm. This spectrum has been 
ascribed to the formation of the safrole metabolite-cytochrome P-450 
complex in the oxidized state (Chapter 4). The formation of this 
spectrum from safrole (41.7 - 417 yM) and cumene hydroperoxide (50 - 
500 yM) was not observed in 20-methylcholanthrene-induced microsomes 
even after incubation at 37° for 30 rain. Furthermore in these microsomes, 
the 438 nm absorbance maximum observed after incubation of safrole and 
NADPH with control or phenobarbitone-induced microsomes (Chapter 3) and 
the exhaustion of NADPH, was not seen.
6.3.3. The Formation of the MDP Metabolite-cytochrome P-450 Complex
in Rat Small Intestine Microsomes and Hepatic Microsomes 
from Other Species
It has been suggested that species and tissue differences 
occur in the proportions of various cytochromes P-450 in microsome 
populations. The results above suggest that the formation of the 427/455 nm 
spectrum may be a sensitive indicator of the type of cytochrome P-450 in 
a particular microsomal preparation. Hence the present work examined the 
formation of the safrole metabolite complex in hepatic microsomes obtained 
from rat, dog, monkey (patas and rhesus) and rainbow trout. Control
FIGURE 6.4.
Formation of the 455 nm Absorbing Species from Methylene-
dioxybenzene in 20-Methylcholanthrene-induced Microsomes
0-01 A
370 410 450 490
Conditions were as described in Fig. 6.2., except that
the substrate was methylenedioxybenzene (417 yM).
microsomes (i.e. obtained from untreated animals) were used in this study. 
All of these species except for the trout were capable of metabolizing 
safrole with the concomitant formation of the characteristic 427/455 nm 
spectrum (Figs. 6.5., 6.6.). It was also observed that in control 
microsomes from the dog, monkey and rat the 427 nm peak was considerably 
higher than the 455 nm peak at a safrole concentration of 208 yM.
The 438 nm absorption maximum of the oxidized complex was 
observed in the dog and monkey both after the exhaustion of NADPH and in 
the presence of cumene hydroperoxide.
The formation of the safrole metabolite complex was also 
observed in microsomes of the small intestine, both NADPH (Fig. 6.7.) 
and cumene hydroperoxide (Fig. 6.8.) were capable of mediating the 
formation of the complex. This result is in apparent contradiction to 
the suggestion of Zampaglione and Mannering (1973), who proposed that the 
haemoprotein of the small intestine microsomes was cytochrome P-448. Since 
the present work has shown that cytochrome P-448 will not catalyse the 
formation of the 427 nm absorbance maximum, nor will cumene hydroperoxide 
mediate the formation of the 438 nm spectrum with cytochrome P-448.
6.4. DISCUSSION
Safrole was found to induce a haemoprotein with different 
spectral characteristics from those of cytochrome P-450 (control or 
phenobarbitone-induced microsomes) and cytochrome P-448 (20-methyl­
cholanthrene-induced microsomes). Since the wavelength for the absorbance 
maximum of the carbon monoxide complex of safrole-microsomes was inter­
mediate between that of cytochrome P-450 and cytochrome P-448, it may be 
suggested that safrole induces both cytochromes P-450 and P-448. However 
this hypothesis seems unlikely because the magnitudes of the n-octylamine
FIGURE 6.5.
Formation of the Reduced and Oxidized Complexes of the Safrole 
Metabolite with Cytochrome P-450 of Dog Hepatic Microsomes
0*0'05 A
mil
Dog microsomes were suspended in 66 mM Tris-HCl buffer (pH 7.4) 
to a protein concentration of about 2 mg ml“*. Safrole (208 yM) 
was added to the sample cuvette, followed by NADPH (400 yM) to 
both cuvettes. The spectra were obtained every 15 seconds. Op 
the exhaustion of NADPH the 438 nm spectrum was observed.
%
FIGURE 6.6.
Formation of the 427/455 nm Absorbing Complex
in Monkey Hepatic Microsomes
?o 4$a aao
Monkey (patas) microsomes were suspended in 66 mM 
Tris-HCl buffer (pH 7.4) to a final protein 
concentration of about 2 mg ml-1. Safrole (208 yM) 
was added to the sample cuvette and the spectrum 
recorded (©-© ). NADPH (400 yM) was then added to 
both cuvettes and the spectra recorded every 30 sec.
FIGURE 6.7.
Formation of the 427/455 nm Absorbing Complex
In Small Intestine Microsomes
0001A
450
nm
430 490410 470
Microsomes from the mucosa of rat small intestine 
were suspended to a protein Concentration of 
3 mg ml”1 in 66 mM Tris-HCl buffer (pH 7.4). 
Safrole (208 yM) was added to the sample cuvette 
and the Type I binding spectrum recorded (©-© ). 
NADPH (200 yM) was then added to both cuvettes 
and the spectra recorded every 30 seconds.
FIGURE 6.8.
The Cumene Hydroperoxide-mediated Formation of the Oxidized Safrole 
Metabolite Complex in Small Intestine Microsomes
0001A
490470450430 nm
Conditions were as described in Fig. 6.7. However 
cumene hydroperoxide (150 pM) was used instead of 
NADPH.
difference spectra were similar with cytochrome P-450 and P-448, while 
that of safrole-microsomes was greatly enhanced. .The reason for this 
increase is unknown. But it is likely to be a result of the de novo 
synthesis of a novel haemoprotein which has either an altered extinction 
coefficient or different binding characteristics with n-octylamine.
Results in this chapter have indicated that marked differences 
exist for the formation of the MDP metabolite-cytochrome complex with 
cytochromes P-450 and P-448. The observation that cytochrome P-448 is 
incapable of catalysing the formation of the 427 nm absorbance peak 
(reduced state) or the 438 nm peak (in the oxidized state) suggests that 
the 427 nm absorbance and the 438 nm absorbance are intimately related, 
while the 455 nm absorbance maximum is different. However this point 
will be discussed in greater detail later.
Preliminary results described in this chapter suggest a 
similarity between the abilities of different species to produce the MDP 
metabolite cytochrome P-450 complexes, since rates of and maximum 
formations of the 427 and 455 nm absorbing complex were similar in dog, 
monkey and rat microsomes obtained from untreated animals.
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7.1. INTRODUCTION
•The apparently irreversible binding ' (frequently termed 
covalent binding) of foreign compounds to hepatic tissue was demonstrated 
nearly 30 years ago by Miller and Miller (1947) after feeding rats a diet 
containing the azo dye butter yellow. Hultin (1957) demonstrated that 
1^ C-methyl butter yellow became preferentially bound to the endoplasmic 
reticulum fraction of hepatic tissue after the administration of the 
compound to animals. Furthermore Hultin (1959) showed that the in vitro 
irreversible binding of aniline and 2-aminofluorene to rat liver microsomes 
was dependent on the presence of NADPH.
The apparently irreversible binding of foreign compounds to 
nucleic acids is generally considered to be involved in carcinogenic, 
mutagenic and teratogenic effects. However much attention has recently 
been focussed on the binding of some drugs and related materials to 
components of the hepatic endoplasmic reticulum (Gillette, Mitchell and 
and Brodie, 1974). The monooxygenation of these compounds is a 
prerequisite for their covalent binding to hepatic tissue (for reviews 
see Gillette et al., 1974; Uehleke, 1974). -
Covalent binding of drug-related material to the endoplasmic 
reticulum has been implicated in the production of hepatotoxic effects. 
Perhaps the most extensive work on this topic is by Brodie and his 
colleagues who have related the covalent binding of phenacetin and 
halpbenzene derivatives to their hepatotoxicities (Brodie et al., 1971; 
Gillette, Menard and Stripp, 1974; Mitchell et al. , 1973; Potter et al., 
1973).
In the light of reports of isosafrole and safrole being 
hepatotoxic agents (Taylor, Jenner and Jones, 1964; Hagan et al., 1965), 
the present study has examined the apparently irreversible binding of ^C- 
isosafrole-related material to rat hepatic subcellular fractions, both
in vivo and in vitro.
7.2. METHODS
Rats were housed in all-glass metabolism cages with 
facilities for the separate collection of urine, faeces and expired 
carbon dioxide. llfC-Isosafrole (specific activity: 1.03-1.19 nCi nmol”*) 
was administered intraperitoneally as an injection in corn oil at a dose 
of 150 mg kg~* daily for four days. Urine, faeces and carbon dioxide 
were collected until 24 hours after the last injection.
7.3. RESULTS
7.3.1. Distribution and Excretion of *^C-isosafrole ,•
Extensive measurements were not made, but typically
approximately 65% of the total radioactivity was excreted in the urine 
within 24 hours of the last dose of 1£tC-isosafrole. A further 10% and 
1.5% of the total llfC were found in the faeces and expired carbon dioxide 
respectively. The observation that only 1.5% of the total radioactivity 
was expired as carbon dioxide indicates that very little side-chain 
oxidation, if any, occurred.
7.3.2. Covalent Binding Studies. I - The Binding of ^C-isosafrole-
related Material to Rat Hepatic Subcellular Fractions In Vivo
Rats were pretreated with *^C-isosafrole as described previously 
for four days. The animals were killed and the livers excized and 
homogenized. Subcellular fractionation and the determination of marker 
enzymes were effected as previously described (Chapter 2). The nuclear 
fraction appeared to be contaminated by whole cells, otherwise very little 
cross-contamination of fractions was observed. The protein of the 
subcellular fractions was denatured using absolute ethanol (66% (v/v)) 
and precipitated by centrifugation prior to extraction with various solvent 
systems (Chapter 2). The extraction procedure utilized appeared efficient 
as negligible quantities of radioactivity were removed in the final 
extractions. Table 7.1. illustrates a typical extraction procedure for 
the microsomal fraction.
A Typical Sequential Extraction Procedure for a Microsomal 
Suspension containing Covalently Bound *^C-isosafrole-
related Material
Extraction Medium Total nCi Radioactivity in Extract
Absolute ethanol (10 ml) 26.2
70% (v/v) ethanol (5 ml) 2.1
0.25 M Tris-HCl (pH 7.4) (5 ml) 2.8
0.25 M Tris-HCl (pH 7.4) (5 ml) 0.65
70% (v/v) ethanol (5 ml) 0.45
96% (v/v) boiling ethanol (5 ml) 0.65
96% (v/v) boiling ethanol (5 ml) 0.10
acetone/CHCl3 (4:1) (5 ml) 0.05
acetone/CHCl3 (4:1) (5 ml) 0.05
70% (v/v) ethanol (5 ml) 0.05
The microsomal suspension, before extraction, contained a total of 
64.25 nCi, hence approximately 50% of the total radioactivity in the 
microsomal fraction was extracted by this procedure.
What appeared to be covalently bound radioactive material 
was found in all of the subcellular fractions examined. Although the 
largest quantity was in the microsomal fraction (0.63 nmol, mg protein *) 
considerable amounts of *^C-isosafrole-related material were identified 
in the other fractions especially the cytosol, which contained 0.33 nmol, 
mg protein-**.
It is unlikely that the cytoplasmic binding was due to 
GSH conjugates of isosafrole metabolites, since one would expect these 
compounds to be soluble in ethanolic solutions and not therefore to 
appear in a denatured protein pellet. Hence it is reasonable to assume 
that the ll|C-isosafrole metabolite was bound to cytoplasmic macromolecules.
Considerable quantities of radiolabel were found in the 
other body tissues, (Table 7.2.). Although these tissues were not 
extracted it seems quite likely that some of the residual llfC-isosafrole- 
related material was present covalently bound to tissue macromolecules.
7.3.3. Covalent Binding Studies. II - The Binding of ^C-
isosafrole-related Material to Rat Hepatic Subcellular 
Fractions In Vitro using Isolated Hepatocytes ;
The covalent binding of 11+C-isosafrole-related material 
was also investigated in viable isolated hepatocytes. Isolated hepatocytes 
were incubated with ^C-isosafrole (175 yM) for 25 minutes at 37° as 
described earlier. The cells were then homogenized and the various 
subcellular fractions were separated. The distribution of marker enzymes 
was similar to that obtained from whole liver, the only significant 
contamination was of the nuclear fraction by small undisrupted cells. The 
protein of the various subcellular fractions was denatured and extracted 
as previously described.
As was found in vivo, the distribution of covalent binding 
in the isolated hepatocytes was quite even throughout all of the fractions.
TABLE 7.2.
Distribution of ^C-isosafrole-related Material in Rat Tissues
Tissue nCi g. wet wt." nmol g wet wt. * % of dose administered
Heart 44.6 37.5 0.008
Lung 83.8 70.0 0.047
Liver 253 213 0.601
Pancreas 966 811 0.170
Spleen 179 150 0.027
Kidney 133 112 0.066
Testis 40.0 33.6 0.012
Brain 17.1 14.4 0.005
Fat Pad 672 565
Muscle 34.4 28.9
Radioactivity in: Urine 65%
• Faeces 10% 
Expired CO2 1.5%
expressed as % of total dose.
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The relatively high level of radiolabel discovered in the nuclear fraction 
was probably due to contamination by whole undisrupted cells.
In general the pattern of distribution of ll+C-isosafrole-
related material was similar 'in vivo and in the isolated hepatocytes. The
main discrepancy was the very large amount of radiolabel found in the 
microsomal fraction after the -in vivo experiment; the probable reason 
for this will become apparent later. Again the high levels of llfC- 
isosafrole-related material covalently bound in the cytosol obtained from 
the isolated hepatocytes is not likely to be due to the formation of 
GSH conjugates (for reasons explained earlier).
7.3.4. Covalent Binding Studies. Ill - In Vitvo Covalent Binding
of 1 ^ C-isosafrole-related Material to Hepatic Micros'omes 
Obtained from Rats after Different Pretreatments
In addition to phenobarbitone-induced, 20-methylcholanthrene-
induced and control raicrosomes, two types of safrole-microsomes were used.
These safrole-microsomes are designated safrole-microsomes 'A' and
safrole-microsomes B1 in the subsequent discussion for convenience.
Safrole-microsomes 'A' were obtained from rats fed dietary safrole
(0.5% (w/w)) for four weeks, while safrole-microsomes 'B' were
prepared from rats fed the safrole for four weeks but then returned to
their normal diet for four days before killing.
Microsomal suspensions (5 ml of a 5 mg ml"1 suspension)
in 66 mM Tris-HCl (pH 7.4) buffer were incubated with 180 yM llfC-isosafrole
(specific activity 0.620 yCi nmol-1) and 1.0 mM NADPH (and a regenerating
system - see Chapter 2) at 37° in a shaking water bath (100 oscillations
min"1) for 30 min. The reactions were terminated by the addition of
absolute ethanol to 66% (v/v) and then the extraction of unbound ll+C-
isosafrole-related material was effected as previously described.
As may been seen (Table 7.5.) much larger amounts of llfC-
isosafrole-related material became bound in the microsomal experiments
than 'in vivo or with the isolated hepatocytes.
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Induction with 20-methylcholanthrene or phenobarbitone 
appeared to increase the amount of covalent binding by about 20 and 100% 
respectively when compared with control microsomes. These findings are 
in accordance with the view that monooxygenation of isosafrole is 
required for the observation of covalent binding.
- Surprisingly safrole-microsomes 'A' (which contained the
inactive safrole-metabolite-cytochrome P-450 complex) were by far the 
most active in promoting the presumed metabolism and subsequent covalent 
binding of isosafrole-related material. Safrole-microsomes 'B1 (still 
slightly induced according to spectral studies, but not containing the 
MDP metabolite complex) mediated only a control level of covalent binding.
The proportion of the total radioactivity, in the 
microsomal incubation, which became bound was very high. In control 
microsomes it was around 10% of the total radioactivity in the incubation 
medium, while in phenobarbitone-induced microsomes it was virtually 
doubled. This is an indication that isosafrole is rapidly and readily 
metabolized in microsomal suspensions. It is interesting to note that 
20-methylcholanthrene pretreatment of animals did not result in a greatly 
increased amount of covalent binding. This could be indicative of either 
a decreased overall rate of isosafrole metabolism by cytochrome P-448 or 
an altered metabolic profile for isosafrole. This latter suggestion is 
supported by work of Zampaglione et al (1973) who demonstrated an 
alteration in the profile of bromobenzene metabolism which led to a 
concomitant decrease in the covalent binding and hepatic necrosis due to 
3,4-bromobenzene epoxide.
7.4. DISCUSSION
Several reasons are apparent for the differences in the 
degree of covalent binding obtained in isolated hepatocytes and 'in D'ivo.
The amount of *^C-isosafrole reaching the endoplasmic reticulum was 
probably grossly different since 'in vivo the animal was subjected to the 
compound for four days, whereas in the hepatocytes only a 25 minute 
exposure was allowed. Furthermore four days pretreatment of animals 
with isosafrole leads to an induction of monooxygenase activity, hence 
increased covalent binding would be observed assuming the same 
quantitative relationship between the metabolites pertained. However, 
allowing for these differences the results obtained in vivo and those 
obtained in the isolated hepatocytes were quite comparable.
High levels of covalent binding to cytoplasmic components 
were found in vitvo using the isolated hepatocytes and in vivo. As 
discussed previously this cannot be attributed to the formation of 
glutathione conjugates of isosafrole metabolites because these would 
not be found in the denatured cytoplasmic protein fraction. Hence this 
covalently bound presumably represents the binding of isosafrole 
metabolites to cytoplasmic macromolecules. Since a considerable proportion 
of the cytosol proteins are enzymes, containing sulphydryl groups, and 
likely epoxide metabolites of isosafrole could be expected to bind to 
these, it would be invaluable in future studies to investigate the effects 
of isosafrole treatment of animals or isolated hepatocytes on the activity 
of enzymes of the cytosol such as alcohol dehydrogenase or glucose-6- 
phosphate dehydrogenase.
Dramatic differences were obtained between the degrees of 
covalent binding to microsomes in vitvo3 in vivo and in the isolated 
hepatocytes. These gross differences are due to a number of factors.
GSH has been shown to decrease the level of covalent binding of many 
compounds and therefore decrease hepatotoxicity (Mitchell et al. , 1973) , 
hence in the present experiments the degree of covalent binding of ^C- 
isosafrole-related material was probably lowered in vivo and in the 
isolated hepatocytes by the formation of various conjugates. However
this is not possible in vitro using microsomal suspensions, therefore 
more active metabolites will be available to bind to the microsomal 
proteins. Another factor contributing to the very large amount of 
covalent binding in microsomes is that the conditions for metabolite 
formation were probably optimal. For example high protein and high 
cofactor and substrate concentrations were utilized in the in vitro 
microsomal experiments. Furthermore in vivo and in the isolated hepatocytes 
the amount of active metabolite is distributed relatively evenly throughout 
the cell, whereas in the microsomal experiments all of the metabolite 
will bind to the microsomal macromolecules.
The rate of covalent binding in vitro has frequently been 
expressed by other workers in terms of nmols bound per mg microsomal 
protein per min, for comparative purposes (assuming linearity of the 
isosafrole covalent binding reaction) the rate of covalent binding in 
these experiments using control and phenobarbitone-induced microsomes 
was 0.346 and 0.7.12 nmol, mg-* min-*. Hence referring to Table 7.6. 
(modified from Uehleke, 1974) one may observe that the degree of isosafrole 
covalent binding in vitro is comparable with if not greater than the 
degree of covalent binding of many other compounds screened.
The difference in the degree of covalent binding in vivo 
and in vitro indicates that the in vitro screen, so often proposed, for 
the detection of hepatotoxic agents may lead to grossly misleading 
conclusions. * Since isosafrole, although weakly hepatotoxic (Hagan et al. , 
1965; Taylor et al.; 1964), results in more covalent binding to microsomes 
in vitro than does bromobenzene and other compounds which are far stronger 
hepatotoxic agents (Table 7.6.). The results obtained using the isolated 
hepatocytes suggest that this system may be preferable for use as an 
in vitro screen for hepatotoxins.
A Survey of Data on the In Vitro Covalent Binding 
of various Compounds to Microsomal Proteins 
(modified from Uehleke, 1974)
Compound
f " ' 1 1
Species
1-----------  ,---- -
**
Covalent Binding In Vitro
d-amphetamine rabbit
*
0.08
antipyrine rabbit <0.03*
benzpyrene rabbit 0.16*
, 1
bromobenzene rat 0.004
rat 0.061*
CCli* rat 0.15
rabbit 0.80*
rabbit 0.30
CHCI3 rabbit 0.26*
CBrCl3 rat 1.44
chlorobenzene rabbit 0.08*
rabbit 0.02
chlorpromazine rabbit 0.08
diethylstilbestrol rat 0.16
furosemide mouse 0.11
halothane rabbit 0.18
hexachlorophene rabbit
*
0.11
naphthalene rabbit
*
0.30
rabbit 0.06
paracetamol rat 0.125
stilbene rat 0.04
* Phenobarbitone-induced microsomes.
** Expressed as nmol compound bound per min per mg 
microsomal protein
The nature of the isosafrole metabolite(s) which 
covalently bind to tissue components is unknown; however, two principle 
possibilities exist. They are the epoxide (I) and the "active methylene" 
compound (II), whether it be a carbanion, carbene, free radical or 
carbonium ion.
CH3-CH-CH-v
(I)
CHo-CH=CH
C: or
^0 y0
^  \ /  \ © 
CH* or CH
(II)
\ /o
or^-0
The "active methylene" compound would be capable of reacting 
with a host of tissue components. However it should be emphasized that the 
interaction involved in the covalent binding of the carbenoid species to 
proteins is not the same as that involved in the formation of the MDP 
metabolite-cytochrome P-450 complex. Since the latter reaction is easily 
reversible (Chapter 5) while the covalent binding to tissue is apparently 
irreversible.
Since epoxides are well known to bind to tissue components 
(Neumann, 1974), isosafrole epoxide may also become bound to tissue 
proteins. Although its isomer, safrole epoxide, is relatively stable and 
can be isolated from the blood and urine of animals pretreated with it 
(Stillwell et al., 1974), the reactivity of isosafrole epoxide may be 
different due to the proximity of the oxirane ring to the bezene ring.
Some of the differences observed in the extent of covalent 
binding after pretreatment of animals with inducing agents, may result 
from the differential stimulation of pathways of degradation for the
active isosafrole metabolite(s). Figure 7.1. indicates the possible
Possible Degradative Routes of Isosafrole Expodixe in Liver
CHq-CH-CH
3 \  / 
0
conjugation 
reactions 
(eg. glutathione)
CHq-CH-CH
I I
OH OH
eg. CH3-CH-CH—
> binding to cellular 
macromolecules 
(covalent binding)
non-enzymic
hydrolysis
CHq-CHjCH
OH
^-conjugation
reactions
i
e. g * sulphate or 
glucuronide
major routes for the degradation of isosafrole epoxide. The activity and 
specificity of epoxide hydrase is stimulated to different extents by 
inducing agents (Oesch, Jenria and Daly, 1971; Oesch, 1972), hence the 
amount of "free" isosafrole epoxide able to covalently bind may vary 
according to the induction regime employed.
Chapter  Eight
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8. DISCUSSION
8.1. The Methylenedioxyphenyl Metabolite-cytochrome P-450 Complex
The present study has demonstrated that MDP compounds are 
metabolized via the cytochrome P-450 system resulting in the production 
of "active intermediates" which are capable of binding to the haem of 
the cytochrome. These complexes generally have Soret absorption bands 
at 427 and 455 nm in the reduced form and at 438 nm in the oxidized fora. 
Similar reduced spectra have been demonstrated using ethylisocyanide, 
although metabolizing conditions are not required with this compound 
(Iraai and Sato, 1966). The absorption maxima at 427 and 455 nm of the 
reduced complex for safrole are in a pH-dependent equilibrium as is the 
case for ethylisocyanide (Imai and Sato, 1966) and piperonyl butoxide 
(Franklin, 1971). It has been proposed that the appearance of the two 
Soret peaks for the ethylisocyanide-cytochrome complex, in the reduced 
state is due to the presence of two readily interconvertible forms of 
cytochrome P-450 under reducing conditions (Imai and Sato, 1966). Hence 
the 430 nm and 455 nm peaks observed on the addition of ethylisocyanide 
to reduced microsomes are due to the interactions of the compound with 
the "430" ("A") form and the "455" ("B") fora of the enzyme, respectively.
An alternative explanation for the 430 and 455 nm absorption
maxima of the reduced ethylisocyanide-cytochrome P-450 complex has been 
proposed by Peisach et al. (1973). These authors believe that the fifth 
and sixth ligands are an obligate mercaptide ligand and a variable non- 
mercaptide ligand. The nature of the latter ligand is dependent on the 
environment of the protein. Furthermore they suggest that compounds such 
as carbon monoxide are only capable of displacing the non-mercaptide 
ligand resulting in the observation of an absorption maximum in the region
of 450 nm, while ligands such as ethylisocyanide are able to displace both
the raercaptide and non-mercaptide ligands resulting in the appearance of 
absorption maxima at around 430 and 450 nm respectively.
Two principle tautomers of ethylisocyanide exist, the 
carbanion and the carbene (Kirmse, 1964):
@  ©
CH3CH2-N=C: f 1 CH3.CH2-NsC:
It is therefore possible that one of these forms displaces 
the mercaptide ligand and the other the variable ligand. The effect of 
pH on the 430/455 ratio may be reflecting either a change in the 
equilibrium of the above reaction, or an alternation in the bond 
dissociation energies of the fifth and sixth haem ligands of the 
cytochrome P-450.
By extention of this argument one may propose a similar 
carbene-carbanion equilibrium for MDP compounds. Since the metabolic 
activation of MDP compounds is a prerequisite for formation of the 427/455 nm 
absorbing spectrum, the difference in the 427/455 ratios found with many 
compounds may be due to slightly different metabolic profiles resulting 
in diverse carbene/carbanion ratios. Alternatively, according to the 
hypothesis of Imai and Sato, the differences in 427/455 ratios may merely 
reflect different substrate specificities for the "A" and "B" forms of 
the enzyme.
As reported earlier, at low safrole concentrations (about
10 yM) only the 427 nm absorbance was elicited, but as the concentration
was increased the 455 nm absorption maximum appeared. This change in the
427/455 ratio could be explained in terms of two metabolites being
involved, with different K values for their formations or differentm
binding affinities for the haemoprotein(s). However the latter possibility 
is discredited since these studies have shown very similar Kg values for 
both the 427 and 455 nm absorption maxima.
Evidence presented in Chapter 4 strongly relates the 427/
455 nm spectrum of the reduced MDP metabolite-cytochrome P-450 complex 
with the 438 nm spectrum of the oxidized complex. Kg values and K ' values 
for the formation of the 455 nm (reduced) and 438 nm (oxidized) complexes were 
identical. However in contradiction with this apparently intimate 
relationship other results have suggested that the 427 nm aijd 438 nm 
absorption bands are closely related while the 455 nm absorbance is some­
what different. Compounds such as piperonyl butoxide which produced a 
negligible 427 nm absorption maximum were also incapable of forming the 
438 nm absorbing complex with microsomes and cumene hydroperoxide.
Furthermore after formation of the MDP metabolite-cytochrome P-450 
complex with NADPH, microsomes and piperonyl butoxide, and removal of 
reducing conditions the oxidized 438 nm spectrum was still not observed.
This is in contrast with observations made using safrole.
The absence of both the 427 nm and 438 nm absorption maxima 
after formation of the MDP metabolite complex using piperonyl butoxide 
could be explained in two ways. First only one piperonyl butoxide 
metabolite is produced and it only displaces the non-mercaptide ligand 
of cytochrome P-450 haem (hence the 427 nm peak is not seen), or secondly, 
if one assumes the existence of two interconvertible forms of P-450 
(Imai and Sato, 1966) that the metabolite is only capable of interacting 
with the "B" form of the haemoprotein. The inability to observe the 
438 nm absorbance in the oxidized spectrum indicates that it is due to 
the same interaction as the 427 nm peak, differing only in its redox state. 
The present work has demonstrated that the spectrum of the reduced MDP 
metabolite complex with 20-methylcholanthrene-induced microsomes (i.e. 
cytochrome P-448) only contained a peak at 455 nm; furthermore in this 
case the 438 nm spectrum of the oxidized complex could not be observed.
This indicates that cytochrome P-448 is similar in its spectral binding 
characteristics to the "B" form of the haemoprotein described by Imai 
and Sato (1966) or that the fifth and/or sixth ligands of cytochrome 
P-448 differ from those of cytochrome P-450, or that cytochrome P-448 is 
incapable of metabolizing safrole to one of the proposed two metabolites 
(carbene and carbanion).
These problems are complex and a fuller understanding of 
the mechanisms involved awaits studies using solubilized reconstituted 
systems.
Other compounds have previously been shown to form "product 
complexes" with cytochrome P-450. For example the amphetamines (Werringloer 
and Estabrook, 1973; Franklin, 1974a,b) and compounds related to SKF-525A 
(Schenkman et al., 1972; Franklin, 1974c) when incubated with microsomes, 
NADPH and oxygen elicit the time-dependent formation of absorption maxima 
at 455 nm. However maxima at 427 nm are never observed. This could reflect 
the inability of the active metabolites of these compounds to bind to the 
"A" form of the enzyme, or to displace the mercaptide ligand. Alternatively 
it may indicate that with the amphetamines only one active metabolite is 
produced, whereas two may be produced from certain MDP compounds.
It is chemically possible that active intermediates 
involving the nitrogen atom are produced during the il/-demethylation of 
amphetamines. Possible intermediates are indicated below for benzphetamine:
Any of these compounds would be capable of binding to cytochrome P-450 
haem, however it is a matter of speculation as to whether any of these 
entities actually exist and bind to cytochrome P-450 during monooxygenation 
of benzphetamine resulting in the formation of a complex absorbing at 455 nm.
The position of the 427/455 nm and 438 nm absorbing 
complexes of MDP metabolites with cytochrome P-450 in the proposed reaction 
sequence of monooxygenation is still not clear. However the present study 
has indicated that both of these complexes are formed after the addition 
of the second electron. Future work utilizing epr and Mossbauer 
spectrometry should identify the exact state of the haem iron, hence 
allowing an evaluation of the significance of the perferryl complex 
proposed by Rahimtula et al. (1974) and Hrycay et al. (1975).
8.2. Induction by Safrole and Isosafrole
The present study has demonstrated that certain spectral 
characteristics of safrole-microsomes are different from those of control 
microsomes. The carbon monoxide and n-octylamine complexes of safrole- 
microsomes showed similarities to those of cytochrome P-448. The 
wavelength maximum of the carbon monoxide complex of safrole-microsomes 
was intermediate between that of cytochrome P-450 and cytochrome P-448.
The "pattern of induction" (with respect to substrates) of safrole and 
isosafrole has similarities to those of the barbiturate and polycyclic 
hydrocarbon classes of inducing agents (Lotlikar and Wasserman, 1972;
Lake et al., 1973; Lake, 1974). On the basis of these observations it 
might be suggested that safrole and isosafrole stimulate the de novo 
synthesis of cytochromes P-450 and P-448, hence the metabolic and spectral 
properties of both of these enzymes would be observed. My work has 
indicated, however, that the magnitude of the n-octylamine spectrum with 
microsomes may be used as an indicator of . induction. The magnitude
(AA nmole-1 cytochrome) of the n-octylamine spectrum in control, 
phenobarbitone-induced and 20-methylcholanthrene-induced microsomes was 
about 0.25 AA nmole"1, but in safrole-induced microsomes this value was 
increased to about 0.39 AA nmole"1. Hence it appears that safrole 
induces a novel haemoprotein which has a different molar extinction 
coefficient and/or different binding properties with n-octylamine.
The presence of the safrole metabolite-cytochrome P-450 complex was not 
responsible for these differences (Chapter 6). This haemoprotein is 
neither cytochrome P-450 nor P-448 but appears to have properties in 
common with both.
The cytochromes induced by hexachlorobenzene (Stonard, 1975) 
and the polychlorinated biphenyls (Alvares et al., 1973) appear to have 
properties similar to those of the safrole-induced cytochrome. Hence it 
would be of interest to examine the n-octylamine spectrum of the poly­
chlorinated biphenyl-induced haemoprotein.
8.3. The Displacement Phenomenon ‘
The safrole metabolite-cytochrome P-450 complex can be 
formed in vivo. The present work has shown that this complex consists 
of equimolecular proportions of a MDP compound—related material and 
haemoprotein. Despite the high stability of this complex it may be 
readily dissociated in vitvo by certain Type I substrates. The time- 
dependent intensification of a Type I compound's binding spectrum with 
safrole-microsomes has been shown to be due to two related phenomena.
First the dissociation of the complex and the displacement of a MDP 
compound-related material from the microsomes, and secondly the binding 
of more Type I substrate to the "released" cytochrome. The nature of this 
MDP compound-related material is presently under investigation.
The apparent binding affinity of the displacing compound 
increases during the displacement process and, as described earlier, 
this may be explained in two ways. Competition for binding may exist 
between the bound MDP metabolite and the displacing substrate; alternatively 
the safrole-induced haemoprotein may play a vital role in the displacement 
reaction. As shown in this thesis, safrole apparently induces the 
synthesis of a novel haemoprotein, hence it is possible that safrole- 
microsomes contain normal cytochrome P-450 in addition to the safrole- 
induced novel P-448 type of cytochrome. The initial binding of the 
displacing compound may be to the uncomplexed novel P-448 type of 
haemoprotein, while the final binding of the displacer may be to both the 
novel P-448 type and the "newly released" P-450 type of cytochromes.
Work is in progress to elucidate which, if either, of these interpretations 
is correct.
The failure of the present work to demonstrate the 
displacement process after the in vitro formation of the MDP metabolite 
complex is intriguing. The results discussed earlier indicate that 
the presence of the safrole-induced novel haemoprotein is vital for 
the initiation of the displacement process. Presumably the binding of 
the Type I compound induces a conformational change in the uncomplexed 
haemoprotein, which in turn effects a change in the conformation of the 
complexed cytochrome via a protein-protein interaction. However the 
actual mechanism by which the added Type I substrate initiates the 
dissociation of the MDP metabolite complex is at present a matter for 
mere speculation.
8.4. The apparently irreversible Binding of Isosafrole-related
Material to Tissue Components
Experiments described earlier (Chapter 7) indicated the 
large extent to which isosafrole-related material became covalently bound 
to hepatic cellular components both in vivo and in vitro. The large 
discrepancies between the in vitro experiments using microsomes, and the 
in vitro hepatocyte and the in vivo experiments indicate that the use of 
a "pure" microsomal system for preliminary toxicity screening has many 
inherent pitfalls.
Comparative studies using differently induced microsomal 
preparations demonstrated remarkable differences in the degree of isosafrole 
covalent binding. Prior induction by 20-methylcholanthrene had little 
effect on the degree of covalent binding although induction by pheno- 
barbitone or safrole doubled the amount of isosafrole binding. The 
large increase of covalent binding after induction by phenobarbitone 
is difficult to explain, since increased rates of metabolism due to 
induction would lead to increased inhibition of the cytochrome P-450 by 
formation of the isosafrole metabolite complex. However it is feasible 
that phenobarbitone induction increases the proportion of a haemoprotein 
which does not complex with MDP metabolites, since it has been shown that 
only about 50% of the cytochrome P-450 of control microsomes is capable 
of complexing with MDP metabolites (Philpot and Hodgson, 1972). Hence 
metabolism of isosafrole may be stimulated rather than inhibited.
The large increase in the amount of covalent binding to 
safrole-microsomes is surprising, since the cytochrome P-450 was 
complexed with safrole-metabolite and should have been inhibited. However 
since the amount of isosafrole covalently bound was increased it appears 
that the uncomplexed safrole-induced haemoprotein has a remarkable 
ability to metabolize isosafrole to the active "metabolite(s)". This 
may possibly be due to an alteration of the metabolic profile for
isosafrole metabolism by safrole-microsomes, or alternatively the safrole- 
induced haemoprotein may be less sensitive to inhibition than cytochrome 
P-450 is. This latter suggestion is supported by the present study and 
by others (Anders, 1968; Franklin, 1972a), which have shown that cytochrome 
P-448 is less sensitive to complexation and inhibition by MDP metabolites. 
This may be the situation with the safrole-induced haemoprotein which 
appears to be of the P-448 type.
This hypothesis should be amenable to test by examination 
of the rate and metabolic profile of isosafrole metabolism, both in vivo 
and in vitro, after pretreatment of rats with various inducing agents.
8.5. Toxicological Implications
Isosafrole and safrole appear ideal model compounds for 
the study of the complex inter-related pathways of intoxication and 
detoxication. The present work has shown that these compounds are 
metabolized by cytochrome P-450 resulting in; (1) the formation of 
stable metabolite-cytochrome complexes, (2) the apparently irreversible 
binding of MDP related-material to hepatic cellular components, and 
(3) the induction of a novel haemoprotein.
An interesting relationship between these three processes 
may be proposed. The formation of the MDP metabolite complex may lead to 
inhibition and alteration of the metabolism of endogenous substrates, 
which might in turn act as messengers modifying protein synthesis and leading 
to the de novo synthesis of the safrole-induced cytochrome. This 
haemoprotein, being of a P-448 type, is probably less sensitive to 
inhibition by complex formation than the normal cytochrome P-450, hence 
the monooxygenation of isosafrole or safrole could still occur. This 
would under many circumstances be an efficient biological protection 
mechanism directed against the inhibition of drug metabolism, if the 
P-448 type of haemoprotein acts as a detoxifying enzyme. However in
the isosafrole situation further metabolism appears to result in an 
increased amount of covalent binding of isosafrole-related material. 
Hence an increased possibility for hepatoxicity would exist.
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Glossary
EDTA Ethylenediaminetetra-acetate
GSH Glutathione, reduced
MDP Methylenedioxyphenyl
NADH Nicotinamide-adenine dinucleotide, reduced
NADP+ Nicotinamide-adenine dinucleotide phosphate, oxidized
NADPH Nicotinamide-adenine dinucleotide phosphate, reduced
Tris 2-Amino-2-hydroxymethylpropane-l,3-diol
K The substrate concentration at which the initial velocitym
of the reaction is half the maximum velocity 
K The substrate concentration at which the half maximal
S '
absorbance change is observed 
log P log10 (octanol-H20 partition coefficient)
Phenobarbitone-induced microsomes Microsomes obtained from animals
pretreated with phenobarbitone
20-Methylcholanthrene-induced microsomes Microsomes obtained from animals
pretreated with 20-methylchol- 
anthrene
Safrole-(isosafrole-) microsomes Microsomes obtained from animals
pretreated with safrole 
(isosafrole) .
